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ABSTRACT 
GENE SET ENRICHMENT AND PROJECTION: A COMPUTATIONAL 
TOOL FOR KNOWLEDGE DISCOVERY IN TRANSCRIPTOMES 
  
 
KARL D. STAMM, M.S. 
Marquette University, 2016 
 
 
Explaining the mechanism behind a genetic disease involves two phases, collecting and 
analyzing data associated to the disease, then interpreting those data in the context of biological 
systems. The objective of this dissertation was to develop a method of integrating 
complementary datasets surrounding any single biological process, with the goal of presenting 
the response to a signal in terms of a set of downstream biological effects. This dissertation 
specifically tests the hypothesis that computational projection methods overlaid with domain 
expertise can direct research towards relevant systems-level signals underlying complex genetic 
disease. To this end, I developed a software algorithm named Geneset Enrichment and Projection 
Displays (GSEPD) that can visualize multidimensional genetic expression to identify the 
biologically relevant gene sets that are altered in response to a biological process.  
This dissertation highlights a problem of data interpretation facing the medical research 
community, and shows how computational sciences can help. By bringing annotation and 
expression datasets together, a new analytical and software method was produced that helps 
unravel complicated experimental and biological data.  
The dissertation shows four coauthored studies where the experts in their field have 
desired to annotate functional significance to a gene-centric experiment. Using GSEPD to show 
inherently high dimensional data as a simple colored graph, a subspace vector projection directly 
calculated how each sample behaves like test conditions. The end-user medical researcher 
understands their data as a series of somewhat-independent subsystems, and GSEPD provides a 
dimensionality reduction for high throughput experiments of limited sample size. Gene Ontology 
analyses are accessible on a sample-to-sample level, and this work highlights not just the 
expected biological systems, but many annotated results available in vast online databases. 
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CHAPTER 1 
INTRODUCTION AND OUTLINE 
 
Explaining the mechanism behind any genetic disease involves two phases, 
collecting and analyzing genetic data, then interpreting those data in the context of 
biological systems. While advances have come to both phases, few tools facilitate both 
phases. My objective is to develop a method integrating several datasets surrounding a 
biological process, with the goal of presenting the response to a test condition in terms of a 
set of downstream biological effects. I hypothesize that heuristic methods overlaid with 
automated domain expertise will highlight relevant systems-level signals underlying 
complex biological conditions that have not been seen by previous methods. To this end, I 
have developed an algorithm called Geneset Enrichment and Projection Displays 
(GSEPD), which visualizes multidimensional gene expression data to identify the 
biologically-relevant gene sets that are altered in response to a test condition. With 
inspiration from state of the art model organism experiments, in vitro experiments, and 
genome sequencing, I present a tool that can help to explain the cellular mechanisms of a 
complex test condition.  
1.1 Introducing the Problem Context 
 
Medical researchers are interested in the diseases with as-yet unknown causes. An 
interesting and longstanding research area is human birth defects, broadly defined as a 
2 
problem present in a newborn [1]. Early genetic screening indicated that “not less than 4% 
of all live births” are impacted by one or more genetic diseases [2]. Presuming a medical 
condition is caused by genetic or environmental factors, or their combination, researchers 
seek to discover the shared cause among independent patient cases.  For some medical 
conditions a common environmental factor can be found through retrospective studies, but 
in the situation of a spontaneous/sporadic birth defect where common environmental 
causes are ruled-out, researchers could search for a mutation impacting a developmental 
pathway. Organ development has not been understood completely; only some vital genetic 
components have been identified [3, 4]. Master control points are known from 
mutagenesis studies of model organisms [5] but subtle effects on complex organs like the 
human brain or heart are still unknown [6].  
Over 100 genes are required to work together to construct a mammalian heart [7] 
and altering any one will cause some form of a visible final trait [8, 9].  Each separate 
gene malfunction can be considered a subtype of the visible trait, and as each gene may 
malfunction in several ways, a few hundred causally-distinct subtypes of the same visible 
trait are generated. The presence of multiple subtypes causes a problem for statistical 
analyses, as each portion of genetic-location specific evidence is relevant for only a subset 
of the cases with a common disease, thereby decimating the power of a case/control study 
[10, 11].  
Genetic analyses usually are performed by examining “case” and “control” groups 
of subjects. Researchers collect genetic information and analyze the genetic information 
for commonalities that segregate the disease case group from the healthy control group 
[12]. The data collection takes several technical forms depending on the technological and 
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social platforms. Gene usage platforms such as sequencing and microarray assays are 
briefly discussed below, each having different strengths, weaknesses, and costs. When 
studying model organisms, one might create controlled animals, but when studying human 
traits researchers need to work with public health organizations or recruit volunteers. The 
prevalence of a disease and the affected population determine the costs and difficulties 
encountered in collecting samples.  For instance, where something like high blood 
pressure affects millions of adults, it is possible to collect tens of thousands of willing 
participants to give a blood sample. Conversely, to directly study organ development 
researchers need to obtain fetal tissue, or work backwards from subjects who have 
completed organ development.  Ethical considerations generally make direct study of 
healthy human tissue impossible, and researchers are limited to incomplete data and must 
piece together information wherever it is available. 
The simplest solution to the problem of hard to collect samples lies in model 
organisms. Model organisms are the inbred and outbred lab rats, mice and lower animals, 
with the simplest model organisms being yeasts and bacteria.  All of these model 
organisms share some biological systems with Homo sapiens from which we can learn 
human-relevant insights. For example, below I present a work involving mice that is 
relevant to heart development, as the mouse heart is very similar to a human’s [13]. 
However, molecular discrepancies exist between mouse and human too, causing 
difficulties for analysis and interpretation of results [14].  Direct measurements of human 
tissues are key, and I present some data on the heart development of humans in Chapter 
2.  
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There exist decades of statistical research in genetic analysis of single-gene traits 
[15, 16]. A trait that has not been explained by single-gene analyses can safely be assumed 
to require multiple interacting factors. Organ development is known to require many 
genomic factors to proceed correctly [1].  Through natural selection, modern life has 
developed redundant systems and safeguards against breakdown of genetic systems [17], 
and modern research identifies redundant systems that have evolved to work around 
deficiencies [18]. Research focus is shifting to networks of genes because many 
biochemical pathways depend on one another, and some proteins fill multiple roles [19].  
A phenotype may not manifest when a single gene is changed.  This makes detecting the 
genetic cause more difficult because a mutation seen in one gene may not wholly cause 
the disease in any one subject’s particular genetic background [20]. The notion of 
penetrance of a gene variant captures the probability carrying the mutation causes the 
disease.  
As illustrated by breast cancer, often a genetic mutation causes an increase in 
probability of disease without directly influencing the visible trait 100% of the time [21]. 
Incomplete penetrance forces researchers to collect probabilistic results across ever-
increasing subject counts. Any mutation in an active gene can be assumed to have some 
measurable effect on some biological systems. Observing the apparent reaction to a 
mutation should reveal the activity of related systems [22]. To short-circuit the statistical 
power problems present in human disease studies of single mutations, my work is directed 
at biological pathways [23].  If a case/control analysis can be reframed as a perturbed 
system reaction, then medical researchers can learn about impacted components of the 
systems involved with the case/control contrast.  
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My work specifically is to facilitate the endeavors of biological research labs 
mired in copious, complex, and incomplete gene expression data. Computational Sciences 
must be brought to bear in an intelligent way to improve research efficiency. 
Computational time efficiency is not the major factor preventing genetic discoveries: 
biomedical research is in need of intelligently directed and data driven hypothesis 
generating tools. Here I present how to merge disparate data types towards the 
overarching goal of explaining systems that have been opaque to traditional research.  
As example datasets, I focus on heart development. Congenital heart disease 
(CHD) is just one of many examples of a situation that has not been solved by traditional 
experimentation, but computer scientists could help with modern data mining and 
processing techniques. Instead of directly assaying every genetic variation, I propose a 
broad systematic search and refinement system that layers the knowledge we do have into 
a coherent picture. Specifically, I have developed free and open source software that 
automates the conversion of gene expression data from human samples into a perturbed-
systems overview, targeting the interpretation and knowledge extraction problems 
inherent in low-sample-count studies.   
1.2 Dissertation Outline 
 
In this dissertation I present 1) background studies motivating the methods, 2) 
software for mining useful knowledge out of imperfect experimental data, and 3) 
applications to published studies where systems-level results were sought. The 
culmination of these three sections is a new method for determining altered systems in 
complex experimental data as alluded to in Figure 1.1. 
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In this work three independent data types are brought together and two major tools 
are developed.  Application of the developed software herein highlights systems level 
expression patterns in genomic datasets, with the objective of directing further research in 
novel directions.  
Starting on the leftmost column of Figure 1.1 are three major unique data types 
accompanying genetic association analyses. “Structural Alteration” refers to the data 
obtained by the analysis of large-scale genomic alterations, and serves as a solid 
foundation for the idea that a set of genes can collectively be responsible for disease 
phenotypes [24, 25].  
 
 
 
Figure 1.1 Flowchart of Concepts Presented in this Dissertation. Blue boxes represent 
data or information sources, red boxes are published knowledge-generating tools I and 
collaborators have produced, with the overall goal is presented in the green box at right.  
Arrows represent information flow, from primary sources in blue, through toolkits in red, 
towards the goal in green. 
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“Functional Annotation” refers to the apriori domain specific knowledge obtained 
from published studies. Primarily Gene Ontology [26], but also the Ingenuity Pathway 
database [27] are used in my work to mark novel findings in the context of prior 
information.   
“Gene Expression” refers to data sets of mRNA abundance, or transcriptomes. A 
transcriptome may be measured from any tissue sample or cell culture, and represents a 
high-dimensional data type. The primary algorithm “Geneset Enrichment and Projection 
Displays” is developed to help analyze and interpret transcriptomic datasets.  
The upper red box, “Regulatory Network,” refers to a novel method and 
application of identifying gene expression dependencies.  In Chapter 2 I describe two 
studies where we built a set of genes relevant for organ development, show their impact, 
then build a network of putative gene-gene interactions and refine the interactions listing 
to testable novel hypotheses.  
The lower red box, “Geneset Enrichment and Projection Displays,” is a novel 
algorithm developed herein (abbreviated GSEPD), specifically aiming to aid biological 
research labs in interpreting their gene expression data. By automating best-practice 
statistical analyses, then recombining data in a novel way, we can understand genetic-
pathway-based sample behavior. GSEPD is the focus of Chapter 3.  
Both of these tools are brought together on the right of Figure 1.1 and in Chapter 
4, where we explore specific case studies in both commercially available stem cells and 
human CHD. I present how these tools shed more light on more complex situations than 
was previously possible.  
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1.3 Motivation to Data Refinement 
 
Observational sciences often work with uncontrolled variability with under-
specified hypotheses, and researchers demand computational support to find signal among 
the noise.  The scale of new measurement technologies in biology is overwhelming: a 
quantitative measure is available associated to every one of the nearly four billion unique 
locations within a person’s DNA. Because no researcher can review each and every 
finding manually, computationally filtering and prioritizing results is key.  If not 
conducted carefully, genome-wide association analyses may inadvertently lead to errors, 
biases and misunderstandings. Therefore a very high degree of certainty (such as p < 10-6) 
is required and often no significant results are achieved [28].  
When no single factor can be pinned as the global cause of a disease/trait, we need 
to consider multi-factor hypotheses. Multi-factor association is susceptible to 
combinatoric explosion [29] where the number of evaluated variables corresponds to the 
dimensionality of the search space. For example, there are only twenty ways to choose one 
gene from twenty genes, but there are 1,140 ways to choose three genes from twenty 
genes. Acknowledging the unfeasibly large scope of searching for pairs or triples of genes 
in the whole genome, my strategy is a heuristic search, using informed priors to boost the 
success rate in a restricted relevant space.  
One may move beyond the DNA to the next level: gene expression, where other 
kinds of analysis can shed light on what is and is not relevant for whichever process being 
studied. Recent advances in data acquisition technologies around genomics are starting to 
shed light on unexplored biological systems, at unprecedented data volumes [30]. New 
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datasets and analysis methods have formed the field of bioinformatics, wherein computer 
science meets biology. Modern high-performance computing resources are often required 
to process and review the results of routine genomic analyses in timely fashion [31, 32]. 
The genomic approaches mentioned above are used routinely by teams of scientists and 
healthcare providers, but improved methods are required to better discover knowledge 
from the volume of data obtained.  
1.3.1 Forward Development 
Standard genetic analysis methods have focused on controllable experiments in 
yeasts, mice, or simulation. Human developmental genetic analysis is ripe for 
computational advancement. Human tissues studies in particular struggle with restricted 
sample collection opportunities, and restricted experimental designs while supporting high 
levels of complexity in data and outcome [33]. 
Low-dimensional outcomes are required for statistical power, but the 
transcriptomic measurements are inherently high dimensional [34]. Recognizing the 
multiple testing problem inherent in a high dimensional test, we turn to intelligently biased 
strategies. Gene sets are the relevant determinant of physiological outcome [35], but 
searching all possible sets for an association signal guarantees spurious results. Therefore I 
propose searching restricted spaces with prior knowledge that certain genes are relevant to 
the organ function [36], or certain gene tuples which are known to interact [37]. Instead of 
reinventing the wheel, we can proceed from the state of the art by building on curated 
knowledgebases available online [26, 38]. 
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1.3.2 Relevant Hypothesis Generation 
Exploratory or observational studies are considered hypothesis-generating in that 
they are not designed to test any precise statistical statement, but rather to give an 
overview and direct more precise future studies. A genome-wide search can produce more 
results than can be followed up on, so restricting the reported results to those with 
likelihood of usability would be helpful. Regarding human disease studies, note that every 
human sample has tens of thousands of unique mutations [39, 40], such that researchers 
need guidance in the form of curated knowledgebases to sift through the results and find 
the real cause of disease or tested condition.  
1.4 Summary 
 
Bioinformatics covers many disciplines: scaled at its smallest, protein atomic 
structures, at its largest, writing the tree of life. I see the study of organ development as a 
high dimensional physical system that is exciting to work with, and an opportunity to give 
fruitful advances to medicine. The software rgsepd, (implementing the method GSEPD) 
can help make discoveries in human tissues studies such as inborn disease, cancers, drug 
treatments, stem cells, or trauma and healing situations.  
Presently it is not exactly known how organs are formed, or why this process goes 
wrong sometimes. Our best organ regeneration methods reanimate cellular skeletons with 
reprogrammed cells [41]. The challenge lies in monitoring ever-smaller and more precious 
subjects and the destructive measurement process. Only very recently has anyone 
measured gene usage in time series for a gestational mammal’s heart [13], and we 
subsequently conducted a study to see what kind of gene-gene causality inferences we 
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could make [7].  To assuage the great cost of bio-specimen acquisition, many studies are 
designed around the bare minimum number of samples able to be obtained and processed. 
The cost and sample size problems create a field of independent laboratories working over 
complex data with simple tools. My goal is to create automatable intelligence to 
accelerate knowledge discovery. 
The goal of this dissertation is to highlight the biological research community’s 
need for data analysis support, and show how computational sciences can help by 
developing automated software tools. Primarily by integrating high-dimensional datasets, I 
have produced a new analytical software to accelerate knowledge discovery in 
transcriptomes. An overview of what follows in the remaining chapters is concisely 
revisited below.  
In Chapter 2 I reinforce the method of searching for clues in complementary data 
types in both human and mouse. Chapter 2 explores two biological studies to set the 
context and motivation of the GSEPD method. In one study, I quantified the genomes of 
humans with and without congenital heart disease. That study of human genomes 
solidifies the concept that some experimental conditions are necessarily uncontrolled 
[25]. In the second study, I build a gene regulatory network from a time series gene 
expression data set in mouse heart ventricle development. The gene regulatory network 
study shows the importance of uniquely verifiable results as distinct from the bulk of 
possible results [7]. These two studies’ result set overlap reveals a core of genetic effects 
necessary for mammalian life, highlighting the utility of independent data types, and the 
associated needs for computational analysis to integrate such data types, regardless of the 
studied condition.  
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In Chapter 3 I briefly review transcriptomics: the measuring and exploration of 
the messenger transcripts responsible for gene usage. New technologies are revealing 
more detail in transcriptomes (such as exon splicing probabilistic effects), and analytical 
methods have fallen behind the needs of biomedical researchers. The standard method is 
to compare samples in batches and collect a list of the dimensions with the most difference 
between two classes, then to query the set of dimensions for meaning. This two-step 
process of collecting genes and querying the set for biological implication is highly error 
prone and does not use the full scope of information present in a gene expression data set. 
I attempt to remedy these concerns by introducing a new software on Bioconductor named 
rgsepd that performs GSEPD: a complete transcriptome analysis from raw sequencing 
read counts through a novel bio-pathway perturbation detection. GSEPD is novel in that it 
simplifies the workflow for a biomedical researcher by identifying segregating gene sets 
between test conditions. I have published rgsepd as an open-source toolkit on 
Bioconductor to let everyone access these automated knowledge discovery methods. 
In Chapter 4 I describe two case studies, their original manual results with limited 
functional findings, and systematic application of both GSEPD and another popular 
functional analysis tool to highlight what further functional findings are possible with 
data-driven tools. The first case study follows stem cell differentiation, tracking the steps 
nature uses to generate pumping muscle cells.  The second case study involves the CHD 
cohort at the Children’s Hospital of Wisconsin and the genomic analyses that have been 
performed to root out the cause of one type of CHD. In each case study three sets of 
results are presented, 1) as originally published by the domain expert, 2) as possible with a 
popular functional analysis tool, and 3) as possible with GSEPD. 
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In Chapter 5 I briefly summarize the findings from GSEPD for the application 
above. Future directions of this avenue of research are identified.  
14 
CHAPTER 2 
BACKGROUND AND MOTIVATION: COMPLEMENTARY 
DATASETS 
 
This chapter covers two published studies where disparate data types that 
complement one another were used to gather a more complete understanding of a shared 
system. An analysis of the structural alterations in human genomes with known cardiac 
status is paired with an analysis of gene regulatory networks in mouse cardiac 
development.  The findings of either study are particular to its context, and careful 
computational integration is required to achieve efficient knowledge discovery [42]. The 
term “complementary” is used to clarify that each study adds to the other synergistically in 
information content. The two studies are incorporated here to highlight practical 
challenges of data processing that guided the development of GSEPD.  
 The first study, CNV2012, is a study of genomes in CHD patients, resulting in a 
set of associations between genes and congenital heart defects [25]. Gene associations are 
moderately useful on their own, reproducing previous studies and evaluating a population 
for its rate of genetic defect. CNV2012 is included here to show that human populations 
carry large-scale genomic differences, so any tool development should account for this 
sample-specific heterogeneity.  
The second study, GRN2014, is where we built upon the gene associations from 
CNV2012. Seeding from the association results in CNV2012, I built a regulatory gene 
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network in collaboration with The Mayo Clinic and Medical College of Wisconsin 
Biotechnology and Bioengineering Center. We predicted a set of verifiable gene-gene 
interactions found in gestational mouse heart.  The predicted gene-gene interactions can 
direct future experimentalists toward hypotheses that are more likely to be true than those 
in a full genome-wide search. GRN2014 is included in this dissertation to show the 
complexity possible in a field like mammalian organ development, and to reiterate the 
need for the more intelligent data usage developed in Chapter 3, such as the usage of pre-
defined gene sets. 
2.1 Candidate Gene Lists and Copy Number Variants 
 
In 2012 we studied a population of healthy and sick children for their prevalence 
of a class of mutation on a candidate gene list to demonstrate and confirm that class of 
mutations is important in the development of the disease [25].  
Candidate gene listing is a common method to trim the experimental scope such 
that the new finding is almost guaranteed to have interpretable results [36]. A major 
drawback of the candidate gene listing method is the limitation in the search space. A 
study using a candidate gene list can only find results among genes on the list. Building on 
established science increases the interpretability of new findings while decreasing the 
ability to discovery truly new effects [43].  
Most genome-wide analyses do not find significant associations [44] unless they 
are restricted to a few dozen genes of relevance, such that the multiple testing correction 
penalty is not as high [38, 45].  As statistical power is linked to subject counts, 
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unrestricted searches require large numbers of independent samples [46, 47], which may 
not be possible with rare diseases or limited budgets.  
Even with nearly a thousand subjects, no significant association was found with a 
genome-wide search. To narrow the scope, a candidate gene list was developed with 
literature review.  “The 100 gene list” of those known to be important for heart 
development was compiled. Table 1 of [12] indicates 85 cited studies that were reviewed.  
We were interested in a particular class of genetic aberration that had not yet been 
thoroughly investigated, the copy number variant. A copy number variant, or CNV, is a 
structural alteration which is difficult to detect by high throughput analyses [48, 49], so a 
study had not been performed investigating their incidence among cardiac development 
cases.  
A CNV is a segment of the genome that is non-diploid. Where most of the human 
genome is expected to have unique sequence, one copy from each parent, non-diploid 
regions are those that somehow become single copy or 3 or more copies. This is a normal 
mutational mode and a mechanism of evolution, but like most mutations, a CNV is most 
often either silent or detrimental. Our study detected CNVs with a microarray technology, 
described in more detail in the literature [25].  Further discussion of CNV detection 
methods is outside the scope of this dissertation.  
Point mutations that damage the gene are known from other instances [50] but are 
difficult to assay in a large cohort. The CNV analysis was an affordable way to broadly 
assay the whole genomes of the cohort.  We used Affymetrix GenomeWide SNP 6.0 
assays, with over one million probes each. 
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After collection of samples, they were analyzed as a batch to account for platform 
biases. CNV segments were called genome-wide and annotated by their underlying gene 
impacts. The number of CNVs found in both a healthy population and a congenital heart 
defect cohort are comparable. An interesting takeaway is that both cases and controls 
show similar counts of CNV losses, the difference being which genes are impacted.  
Affected individuals have nominally more gain segments, but even unaffected individuals 
tend to have >5 segments, indicating some level of genomic instability is normal.  
2.1.2 Six Subtypes Syndromic – Phenotypic Refinement 
In the CNV2012 study, there were 958 subjects with various forms of CHD. If all 
958 shared a single causative genetic defect, it would be apparent. However, no single 
factor was identified, and the implication is that the evidence is spread across several 
different causes. To address the issue of multiple potential causes, the subjects were 
labeled with 42 separate diagnoses by domain experts, which were regrouped into six 
categories. The individual diagnoses are categories summarizing unique individual 
variation by defined codes (specifically the EPCC 2011 coding scheme). The six 
categories are “syndromic” in that they represent major named conditions. We 
hypothesized the categories would show similar genetic burden profiles. We showed the 
prevalence of various CNVs in various groupings of subjects. 
There is reason to believe similar phenotypes have similar causes, i.e. heart valve 
defects having shared genes. In biological genetics it is known that one or more genes are 
responsible for various physical systems, and the genes’ perturbations yield various 
related outcomes [51]. Continuity of causation is key to the belief that gene sets can 
inform complex outcomes [36]. 
18 
A Fisher’s exact test identified 21 genes as significantly differentially impacted by 
CNV among cases and controls. This re-verification of candidate genes cements their 
importance as cardiac development products. Previous indications for each gene came 
from varied platforms and study populations; no genome-wide analysis had been 
performed.  
A result of CNV2012 was the “spectra” or frequency sets of CNVs at each 
analyzed gene. Figure 2.1 notes the rates of gain and loss in each as a frequency with 
standard error bars and chromosomal location. The results indicate genes may be present 
in multiple copies or deleted entirely in both sick and healthy individuals.  
The major takeaways from the CNV study for us are the use of a literature-review 
sourced candidate gene list as a technique, and that precisely phenotyped results are a key 
to precision.  Tables in the CNV manuscript list the genes identified by literature review, 
as well as the CNV findings verifying their association. 
The number of gene copies drives the amount of gene-product produced, and is 
therefore referred to as a gene’s dosage. Higher or lower than normal dosage results in an 
amplification or reduction in the available proteins, which may cause disease [52]. The 
abnormal gene dosage may not always lead to disease, due to the body’s regulatory 
systems that control gene expression [19]. These systems are referred to as “regulatory 
networks” as proteins, genes, and DNA interact with each other to coordinate 
development [1, 53]. 
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Figure 2.1 CNV Frequency Spectra. Calculated incidence rates of CNV gains and losses 
in three cohorts. In red, CHD cohort is the Children’s Hospital of Wisconsin congenital 
heart disease group. In green, CHOP cohort is the Children’s Hospital of Philadelphia 
healthy group and can be considered young controls. In blue, MFHS cohort is the 
Milwaukee Family Heart Study healthy group and can be considered elderly controls.  
Vertical error bars represent one standard error from the mean in the estimated sampling 
distribution.  For example, gains over gene FKBP6 (chr7, just left of center) occur in all 
three cohorts, while losses of the same gene are only seen in the CHD cohort, implying a 
loss could cause CHD. The red point near the top of the diagram shows an 8.5% rate of 
copy number gains at gene RUNX1 in the CHD cohort, mostly indicative of Trisomy 21 
patients.  
 
 
2.2 The GRN2014 Study 
 
The second example source of a complementary dataset comes from our GRN2014 
study [7].  There we built and refined a model of the gene regulatory effects necessary to 
construct a mammalian heart.  That study constructed a regulatory network, and involves 
20 
model organisms, small sample sizes, tissue specificity, time course dynamics, and 
uncertainty. Our focus was on providing relevant verifiable results. The first step produced 
millions of putative gene-gene regulatory interactions, which were later pared down to 
those that are identifiable, testable, and likely.  The result is a shortlist of actionable 
insights. We estimated correctness via overlap to a gold standard in gene-gene interaction, 
Ingenuity Pathway Analysis [54]. 
2.2.1 Mouse Heart Development Dataset 
Thanks to a partnership with the Todd and Karen Wanek Foundation for 
Hypoplastic Left Heart, in 2014 the Mitchell Lab at The Medical College of Wisconsin 
was part of a data-sharing agreement with the Nelson Lab at Mayo Clinic. We had early 
access to a unique dataset. Starting from a collection of mouse embryonic tissues in time-
course, we had access to the gene expression dynamics of the developing heart for the first 
time [13].  
A time series gene expression dataset is distinct from a case/control study in that 
we have sequential measurements of transcriptome and a notion of causality. By 
measuring the same organ’s transcriptome at various stages of development, we can see 
gene expression evolve through the course of the experiment. We know that 
transcriptomic analyses are sensitive to the cell type peculiarities, so measuring a heart as 
it grows is key to learning about that process. 
The process by which cells grow and divide is regulated by the chemicals present 
within them [1, 55, 56]. A gene regulatory network (GRN) is a graphical representation of 
the factors that activate or deactivate each other at the gene level. The network is a 
graphical representation where genes correspond to vertices, and interactions are 
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represented by edges. The GRN2014 study was an attempt to deduce the GRN of the 
developing mouse heart by numerically exploring the dynamics and modeling 
multidimensional differential equations [7, 57].  
2.2.2 Method 
Our analysis used a parallel computational technique to fit models to the data, and 
report which genes seem like they could be regulators of other genes based solely on their 
time course dynamics [57]. For example, gene A increasing one time step before gene B’s 
rise is mild evidence for A driving B. This is known to be a hard problem computationally 
because every gene may impact every other. A network (vertex graph) is created by 
default with every possible edge present, and the edges can be evaluated for significant 
coefficients.  This is computationally intractable in a genome-wide sense, and with limited 
data many possible network configurations are equivalently supported. Pre-supposing a 
sparse network with effect propagation leads to a computational shortcut [58]. Each gene 
is instead evaluated independently and repeatedly as in a random forest technique, and 
only later overlaid as a probabilistic network.  A ‘confidence’ threshold then filters the 
network to a sparse collection of the most plausible configuration, by dropping edges that 
occur with less than a specified frequency. For a detailed description of this method, see 
the Supplemental Materials of [7, 57]. 
A major drawback with this method is that many genes may share a time course 
profile. For example, any two genes that have the same expression dynamics could fill the 
same role in the network. Although we named the nodes with their originating gene, the 
software is agnostic to gene name metadata, and represents myriad potential connections. 
Each node could represent many genes, and each edge represents the product of the node 
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cardinalities [59]. We needed a way to prevent reporting high-multiplicity edges because 
they represent gene-gene interactions with a low likelihood of reproducibility when the 
gene products are physically tested.  
2.2.3 Assaying A Gene Dynamics’ Uniqueness 
To clarify which gene profiles are similar to one another, any distance metric can 
be used, although which metric is the most appropriate is a difficult question in general. 
The data set was a branching time course. Each gene was evaluated once for the first few 
time points, and in two tissues (left and right ventricle) when the fetal development was 
complete enough to differentiate them.  The network was developed only on one heart 
ventricle, but we know the genes to be differentiable using all data. The gene expression 
unit of measurement here is an arbitrary product of the microarray technology, a relative 
fluorescence score, which was normalized to (0-1) at each time point.  The normalized (0-
1) scores at fifteen measurements produce a data point in a unit hypercube of R^15 as 
shown in Figure 2.2.   
To evaluate the expectation that many genes share a similar profile without 
defining the similarity threshold, we used a clustering technique called the self organizing 
map (SOM) [60]. The SOM algorithm performs clustering on a predefined topology.  An 
example of the SOM algorithm behavior on a 6x6 hexagonal grid is shown in Figure 2.2, 
where all gene profiles are organized. The self organizing map is so-named because it 
automatically places data points into identifiable clusters that are locally similar, thus 
reducing the possibly high dimensional input vector to an element in the finite grid. The 
SOM algorithm puts elements into a regular grid and iteratively moves each data point to 
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the grid coordinate that best represents its properties. Thus a finer grid yields more 
possible clusters with an enforced similarity within each grid cell. 
 
 
 
Figure 2.2 Example Self-Organizing Map (SOM) Schematic. A SOM of the 
GRN2014’s mouse time series data is shown on a 6x6 hexagonal grid. The shading shows 
the number of genes per cell. The canonical profile is drawn with a red curve within each 
grid cell. Each circle represents a graph of gene expression profile over time, with the 
vertical axis representing gene expression between 0 and 100%, and the horizontal 
denoting the time-course. The cell fourth from the left on the bottom row shows a highly 
populated cell, where more than seven hundred genes are initially turned off, then on, then 
off again through the time-course.  
 
 
 
 
After ten thousand iterations of randomly sized SOM grids, each gene was 
clustered together with others at varying degrees of precision (grid resolution). Two 
dimensional SOM grids were used with random numbers of rows and columns sampled 
between 4 and 50. Two examples from the 10,000 clusterings are presented in Figure 2.3. 
Resampling the SOM algorithm yields a similarity metric as a percentile of co-clustering 
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agnostic to the originating R^15 space.  Genes that co-clustered more than 80% of the 
time are said to have the same profile, so similar that they might serve the same role in the 
numerical network model (Supplemental Methods of [7]). An important caveat to a 
numerical model is that any number of genes with equivalent input profiles can play the 
same role in the final output network, and the numerical model cannot differentiation 
between these genes. 
 
 
 
Figure 2.3 SOM Similarity Clustering. Two examples of different resolution SOM grids 
on the mouse time series gene expression data. At left is a 4x4 grid of all genes, each 
subplot consists of the time courses that are classified by the SOM into the corresponding 
cell. The vertical axes are 0-100% expression, and all horizontal axes are time. The 4x4 
grid is quite coarse and broadly overlays similar profiles. At right is a 12x12 SOM of the 
same data clustered more finely.  
 
 
 
 
To convert the collection of SOM-based clusterings to a single canonical cluster, 
some threshold of co-occurrence is required. Ten example genes’ co-occurrence results 
from the 80% and 90% thresholds are presented in Table 2.1, and the 80% level was 
finally used as the threshold and definition for similarly expressing genes throughout the 
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time course. Clusters with many genes co-occurring are going to have poor uniqueness 
with respect to regulatory interaction predictions. 
Each node in the network was expanded from one gene to N, encompassing all 
similarly profiled genes. Each edge then truly represented N1*N2 possible edges, where N1 
is the number of genes with similar profile to the source node, and N2 is the number of 
genes with similar profile to the destination node. Due to the numeric nature of this 
analysis, any genes with a shared expression profile were interchangeable in the network.  
 
 
GeneID Name 
80% 
Cluster 
ID 
80% 
Cluster 
Size 
90% 
Cluster 
ID 
90% 
Cluster 
Size 
11287 Pzp 1 27 1 27 
11304 Abca4 2 11 2 3 
11305 Abca2 3 104 3 39 
11307 Abcg1 4 47 4 1 
11352 Abl2 5 1 5 1 
11363 Acadl 6 3 6 1 
11364 Acadm 7 7 7 6 
11370 Acadvl 8 65 8 14 
11409 Acads 9 41 9 22 
11419 Accn2 10 2 10 1 
Table 2.1 Co-Occurrence Clustering Statistics. Top ten genes by ID number of a table 
of all genes involved in the iterated SOM clustering scheme to identify unique profiles. 
The 80% and 90% cutoffs show progressively more stringent clusters, for example the 
second gene Abca4 is identified as Cluster#2 with 11 genes at the 80% threshold, but just 
three genes at the 90% threshold.  Regulatory network predictions involving Abl2 can be 
called unique to that gene, while regulatory network predictions involving Abca2 are 
unlikely to be fruitful, with more than 100 other genes sharing its curve at the 80% similar 
threshold. 
 
 
Some of the originally proposed edges came to represent thousands of potential 
configurations, decimating the interaction’s verifiability in future experiments. Therefore 
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we only reported findings on edges with sufficient uniqueness. A z-score filtering step 
culls low-uniqueness candidate interactions. 
A functional annotation was used to evaluate whether predicted interactions 
involve genes with known similar function. The functional overlap adds independent 
evidence of the veracity of an interaction. Using the Gene Ontology to note which genes 
in the network were known to perform which functions: each gene has a series of 
annotations through the GO hierarchy. The leaf node in the GO hierarchy and the path to 
the root in the GO hierarchy define a set of increasingly general annotations. All annotated 
genes are annotated with the root node of the GO hierarchy. Any two genes’ paths through 
the GO hierarchy have an intersection. The cardinality of the intersection is a measure of 
the degree of known functional similarity between the two genes. We used the Jaccard 
index to score the similarity of these annotation sets for every pair of genes. The Jaccard 
index measures similarity between sets by measuring the cardinality of the intersection as 
a fraction of the cardinality of the union. For example, the sets (A, B, C) and (C, D, E) has 
Jaccard similarity 1/5 because they share one element from a universe of five. The score 
was called the GO term overlap (GOTO). 
The GOTO score was then used to prioritize gene-gene interactions with a higher-
than-zero apriori likelihood of biological relevance due to the genes’ GO annotations.  
The GOTO score and the uniqueness z-score were scaled and a weighted average was 
used as a “Fidelity” score. The weights were determined by evaluation against a gold-
standard database of gene-gene interactions [7].  
The available gold standard is a commercial database mentioned above, Ingenuity 
Pathway Analysis. Ingenuity Pathway Analysis is a curated online resource identifying 
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edges of its graph via text mining and manual review [54, 61]. For each gene in the study 
we downloaded the participating interactions from Ingenuity Pathway Analysis and 
screened them for our predicted hits. The details of this analysis are in [7], and by 
recapitulating known gene-gene interactions, the putative interactions are granted higher 
confidence. GRN2014’s result is a table of newly proposed gene-gene regulatory 
interactions that take place in the developing heart, filtered to biological relevance and 
uniqueness (excerpted here as Table 2.2).  The interactions become pairs of genes for the 
multi-hit hypothesis of disease etiology. Pairs of genes now strongly believed to be 
working together on cardiac development and they constitute a resource for knowing 
which genes are more likely to cause CHD. 
 
 
Source Verb Target IPA 
Myom1 activates Myom2 No 
Hbb-bh1 activates Hbb-y Yes 
Hbb-bh1 activates Hba-x Yes 
Hba-a1/2 activates Hbb-b2 Yes 
Foxa3 activates Nr6a1 No 
Foxa3 activates Foxa1 Yes 
Lama3 inhibits Lama4 No 
Sox7 activates Fli1 No 
Sox18 activates Sox7 No 
Table 2.2 Predicted Gene-Gene Interactions. Results from GRN2014 Table 1 indicating 
the highest fidelity gene-gene interaction predictions [7].  Column IPA notes whether the 
gene pair was found in the Ingenuity Pathway Analysis search.  
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2.4 Summary 
 
The state of the art in human gene association studies involves a literature review 
of the condition of interest to generate a list of possibly important genes, creating a 
candidate gene list.  The list could be evaluated for altered dosage (CNV) in 
developmental patients. The confirmed genes are re-evaluated in a different context, in 
this case a mouse-based gene network study performed with several outside collaborating 
laboratories.  
The results from the GRN2014 study combined with the CNV2012 give 
complementary views on heart development. For example, in Figure 2.1 we see a small 
percentage of CHD patients carry CNVs (of both gain and loss types) at the gene SOX7.  
Table 2.2 reports the top ten interactions ranked by fidelity. Sox7 is indicated twice, as an 
activator of Fli1 and downstream of Sox18. SOX7 is known to be important for heart 
development but its function was unclear [62]. FLI1 is known to be important for tissue 
development in a general sense: it has been associated with sarcomas and leukemias [63]. 
Bringing these two studies together yields novel approaches to heart development 
research. Many other refined predictions are available, due to the methodology of 
integrating complementary datasets. 
The techniques shown in GRN2014 could be applied to other data types. 
Whenever a systems analysis produces a list of putative findings, it is helpful to provide a 
fidelity ranking so other researchers may pursue only the best results.  Computational 
systems biology studies may report thousands or millions of hypothetical findings [64, 
65], but the results can be difficult to integrate with low-throughput experimental 
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techniques. When presented with many putative results researchers may be more likely to 
follow up hypotheses that are easier to confirm [66], inflicting undue bias to further 
research paths.  In the GRN study we specifically addressed these issues by measuring 
how verifiable and how apriori-likely each reportable finding is.  
Using completely separate experimental protocols, it is possible to refine a view on 
a core subject. The methods of combining data from these two sources (each of which also 
draws upon other databases) culminate in a reliable picture of cardiac development, not 
possible by previous simpler analyses.  Cardiac development is just one example of a 
system where sample collection is difficult, and new data analysis methods are needed. 
The CNV2012 study serves to highlight how differences between individuals are 
unavoidable in human tissues analyses, emphasizing the need for better tools. The 
GRN2014 study serves to highlight how automated searches in a large space often 
produce too many results to follow up on, and emphasizes the need to collapse results 
along apriori biologically defined gene sets. Chapter 3 introduces the software rgsepd, 
using these two principles to facilitate systems-level analyses when the data available has 
more measurement dimensions than samples available.   
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CHAPTER 3 
TRANSCRIPTOMICS AND THE GSEPD 
 
Often considered a synonym to transcriptomics is the exploration of the 
“transcriptome” or the genome of transcripts. A transcript is a gene isoform messenger 
RNA, or one particular blueprint for a protein. Almost every gene produces several forms 
of protein through a process called alternative splicing: therefore the transcriptome is 
larger than the genome. Alternative splicing is a common feature of higher organisms that 
boosts the complexity possible from the genome [67]. A single genome can produce 
myriad tissue-types in different contexts, and therefore transcript-level analyses are vital 
to the understanding of genetic diseases. In this chapter I explain some techniques popular 
in exploring the human tissue transcriptome, and present a new software algorithm 
Geneset Enrichment and Projection Displays (GSEPD) designed to facilitate the extraction 
of important features from a transcriptomic data set.  
3.1 Introduction 
 
Why is the transcriptome important? A common belief is that the genome defines 
the species, but the complexity of various tissue types is reliant on various levels of gene 
usage at various times. The transcriptome is the set of all transcripts for an organism, and 
the word is used synonymously with a numerical measure of gene usage: for each gene 
and in each location. It is a spatio-temporal measure of a high dimensional quantity. A 
snapshot of the living cell captures the state, and due to the dynamic nature of living cells, 
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many such snapshots are required to get an average measure of a cell and its variability. 
Measurement of mixed-cell tissues induces another layer of complexity to transcriptomic 
analyses. 
The modern technique to query the transcriptome is RNA Sequencing, or RNA-
Seq for short. In this method, messenger RNA is isolated and loaded into a sequencing 
machine. The resulting data are sequence reads. With some pre-processing the sequence 
reads can be converted to a quantitative measure per transcript.  Given a reference 
“transcriptome” we can have a finite set of dimensions measured. The human 
transcriptome consists of about 35,000 transcripts referred to by their RefSeq ID# in the 
form NM_123456. A single measure then is a vector of cardinality about 35,000.  This 
would have to be measured for each cell type, sensitive to location, and any other 
covariates.  
Early measures of the transcriptome were limited by the available technologies. 
For example, before high throughput assays were available, mRNA levels were measured 
individually and relative to another so-called housekeeping gene, or normalizer [68]. 
Several genes were found to be “markers” as they were apparently specific to the cell type 
being studied. When one gene was found active only in one cell type, it became the de 
facto standard marker for that cell type, and is historically used to identify the cell type, 
and even classify related cell types [69]. Today, cells go through stages defined by their 
markers.  With the advent of higher throughput measures we see more nuance. 
A researcher who aims to characterize a cell’s state would use RNA-Seq as the 
proxy for protein production. Single gene measures were not good enough to see higher-
level functions and complex developmental orchestration. Canonical pathways developed 
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over time with databases coming in later to help broaden the scientific corpus and let more 
researchers access an ever-broadening understanding [70, 71].  Now researchers may 
focus on one or more pathways and perturb the cells with some experimental condition, 
then see the results in the perturbation of the transcriptome. The result of a simple 
experimental condition is a multitude of gene expression changes. Single gene assays 
cannot explain the whole picture, whereas transcriptome-wide analyses overwhelm and 
hide the nuance to the researcher. 
RNA-Seq showed great promise to finally capture a genome-wide picture of the 
transcriptome with digital precision [72]. RNA-Seq finds many genes active in a tissue 
sample. With higher resolution and sensitivity than the older technology, the resulting lists 
of apparently-active genes can grow considerably [34]. Following this advancement there 
was a paucity of analysis software to help researchers interpret the mass of data.  
Several tools came out in rapid succession to help with gene quantification from 
the sequencing data. Bowtie was developed to align the reads to a reference genome [73]. 
Tophat was developed to find new splicings and new isoforms while aligning reads to a 
reference genome [74]. STAR later was introduced to speed up alignment to a known 
reference [75]. Cufflinks was developed to compute probabilistic quantification to novel 
isoforms [76]. Detailed surveys of RNA-Seq data analysis tools have been published [77, 
78]. These transcriptome tools helped capture measurements, but not interpretation of the 
high dimensional results.   
Carefully designed experiments are the direct method for simplifying 
interpretation. A differential gene expression experiment is like subtracting two samples: 
the difference is apparent and attributable to the experimental condition (subject to 
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replication). So differential expression is a common term we will be using often. The gene 
level difference is fundamentally high dimensional, with one measure per gene, and 
therefore difficult for people to visualize and understand.  
Unfortunately pathways can easily be missed with this paradigm: cellular systems 
are more complex than any one researcher’s field of expertise. Each researcher has 
expertise in a few biological functions and can recognize differences in expected 
pathways.  By looking at the personally understandable subset of gene changes, 
researchers may miss broad systems level changes [20]. The result is that truly novel 
findings have the potential to routinely go unseen. The objective of my dissertation, as 
mentioned in Chapter 1, is to develop a tool to aid researchers in exploring gene 
expression experiments without being biased to the pathways they already are familiar 
with.  The newly developed tool leverages online databases to further expand our 
perspective in order to extract additional information from annotated gene sets. 
3.2 Review of Gene Expression Exploration Techniques 
 
Exploration of the transcriptome started with individual assays of a presence or 
strength of a known RNA sequence via qPCR or gel technologies. These technologies 
focus on a given sequence and measure the expression of the gene, but are time 
consuming. The researcher was limited to assaying sequences that were already well 
known. As the database of known mRNAs grew, and technologies miniaturized, a 
fluorescence microarray was developed to assay thousands or hundreds of thousands of 
sequences in parallel.  Finally the researcher can assay a sample’s whole gene activity, 
albeit in a relative way. Later as sequencing technologies matured, direct RNA mass 
34 
parallel sequencing was developed to get a real picture of the native sequences without 
microarray design limiting the view. However, sequencing technology brings technical 
hurdles to normalization, absolute quantification, and data preprocessing.  RNA-Seq is 
widely recognized as a more accurate method (over microarray), by directly identifying all 
mRNA molecules of a sample, at a cost of several thousand dollars per sample [79]. Due 
to the high cost and effort required in sequencing, the microarray technique is not 
completely obsoleted, since its limited view is sufficient for many experimentalists.  Both 
technologies give a very high dimensional quantitative measurement, leading to 
challenges in statistical analysis and interpretation.  Both technologies suffer the curse of 
dimensionality, which I am focusing on alleviating. 
3.2.1 Differential Gene Expression 
The main goal of a transcriptomic analysis is to elucidate the gene usage of a 
sample. Without contrast, a measurement is meaningless, so usually two or more classes 
of samples are compared, and what we look for are “differentially expressed genes” 
(DEG): those genes that are in use differently.  Genewise differential expression is an 
analysis requiring statistical models to determine if each gene is expressing a significantly 
different level between the sample classes. Simple direct inspection will almost always 
show a gene varying in usage between samples, so something like a Student’s t-test is 
required. In the case of transcriptomics, the variance is high but parameterizable with 
respect to other sample properties; so specialized tools have been developed [80]. The 
computation to find truly DEG is not straightforward, as the numerous technical biases of 
each experiment must be controlled for [81]. Many tools exist to facilitate these 
experiments, such as limma, edgeR, and DESeq2 [72, 80, 82-84]. The result of computing 
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DEGs is always a list of genes or gene transcripts, each associated with a measured 
change between the sample means, and a p-value from the hypothesis test “this gene was 
unchanged between sample classes”. Depending on the experimental design and control, 
the resulting DEG list may be a few genes, or hundreds to thousands of genes.  
3.2.2 Functional Annotation 
After collecting a list of DEGs, the next question would be “What do these genes 
do?” or “What biological function do these genes represent?” Since the beginning of 
genome-wide testing, interpretation of results has been a challenge. Often the goal of a 
transcriptome experiment is not a list of genes altered, but instead knowledge of biological 
processes impacted. Several interactive tools exist for researchers to enter a set of genes 
and infer their general function from existing results presented in the peer-reviewed 
literature [85-88].  Table 3.1 is an overview of functional analysis tools. Gene Set 
Enrichment Analysis (GSEA) is one of the original gene set analysis tools, identifying 
functional commonalities in various gene set data, as in differential expression results 
[88]. GSEA can cite studies that have found a particular gene list, and thus GSEA gives 
context to a differential expression result. The contextual result is also a limitation of 
GSEA, as the previous studies it draws from are likely designed with incomparable source 
material (for example seeing your gene set has a similar profile to a drug study of a 
particular tumor is not a particularly usable result.) The next element of Table 3.1 is 
DAVID, a website with several analysis tools including functional evaluation of gene sets 
[89]. DAVID is popular with biologists due in part to its simple user interface, and breadth 
of results. The broad result set is also a drawback: applicability, reproducibility, and 
significance of the findings can be questionable. IPA is another web-tool for inferring 
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meaning from a gene list. The company that owns IPA, QIAGEN, collects both public and 
manually curated gene associations. The IPA service’s knowledgebase is considered one 
of the most complete and informative, but comes with a paywall, steep learning curve, and 
can provide hard-to-interpret results like GSEA. The fifth entry of Table 3.1 is GOSeq 
[90], an R/Bioconductor [91] toolkit that performs a statistical analysis of a Boolean-
flagged gene ID list to provide a set of Gene Ontology (GO) results. GOSeq is robust and 
highly available. The drawbacks are that it only draws from a single data source, offline 
installation/maintenance of the GO database can be cumbersome, and any notion of effect 
size and individual gene behavior is lost. The final entry is GeneMania, available at 
genemania.org, which is a Flash based application that mines several datasets for an input 
gene list. Like DAVID and IPA, GeneMania provides interesting results with little regard 
for reproducibility or significance.  
GSEPD uses GO [26] as a functional knowledgebase agnostic to tooling. The GO 
consists of three tree data structures, the Biological Process, the Molecular Function, and 
the Cellular Component. Within each are hundreds of thousands of “terms” gaining in 
specificity as one traverses down from the root node. GO annotations are manually 
curated by an open-source process, and have become a worldwide free resource for 
annotating multiple functions to each gene. In this dissertation a gene set generally refers 
to a GO term, which is a single node in the hierarchy. A broad node is one near the root of 
the hierarchy, such as GO:0044238 “primary metabolic process” with over 9,000 genes.  
In contrast, a precise node contains very specific biological processes such as 
GO:0033188 “sphingomyelin synthase activity” which pertains to just two genes. By 
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using GOSeq within GSEPD immediately after producing differential expression, 
significantly upregulated or downregulated GO terms are computed [90].  
 
 
Tool 
Name 
Online Input 
Type 
Database Visualizer Programming 
Required 
Depends 
rgsepd No 
 
Genome 
wide read 
counts 
Gene 
Ontology 
Expression 
heatmaps, 
PCA, GO 
scores scatter 
Minimal data 
preparation 
R, 
Bioconductor 
GSEA Website Significant 
gene list 
Multiple Gene ranks Minimal data 
preparation 
None 
DAVID Website Significant 
gene list 
Multiple None No None 
IPA Website 
and Java 
Significant 
gene list 
Proprietary Association 
web graph 
No Paid Account 
GOSeq No Significant 
gene list 
Gene 
Ontology 
None Yes R, 
Bioconductor 
Gene 
Mania 
Website Significant 
gene list 
Multiple Association 
web graph 
No Adobe Flash 
Table 3.1 Overview of Functional Analysis Tools. Six methods to calculate functional 
consequences of an expression dataset are compared in the table.  Online refers to the 
installation of the tool, where “No” means the tool is a local installation, available in 
perpetuity, and “Website” means the tool is accessed remotely, and subject to change or 
unavailability.  Input Type refers to the data given by the user: read counts or gene 
names. Database refers to the source of functional data: where most tools aggregate many 
studies; rgsepd and GOSeq rely on the curated Gene Ontology hierarchy. Visualizer 
refers to the figures generated by the tool. Programming Required refers to the technical 
skills required of the user. Depends refers to the third-party software installation required 
of the user.  
 
 
 
3.2.3 Enrichment and Projection Display 
With functional analysis in hand, researchers could see gene sets X,Y and Z are 
perturbed, and immediately the question becomes “Which differentially expressed genes 
are part of those sets?” Noting the genes underlying a set consists of a database join 
operation. The listing of genes by their GO terms becomes lengthy and therefore difficult 
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to interpret, as the results are on the order of magnitude of the number of genes times the 
number of GO terms. A need remains for a way to show that a gene set was not only 
significantly perturbed, but segregates the samples by gene expression. The simple 
solution to determining if a set segregates samples is a vector projection.  
I developed a software package named rgsepd to implement GSEPD in 
performing automatic differential expression, functional analysis, and the novel gene set 
projection, creating a score for each sample to each gene set (GO term). With a simple 
user interface, rgsepd allows researchers to produce differential expression lists, GO 
functional analyses, and the cross-product: a mapping of which genes are perturbed within 
each gene set. The projection uses simple vector calculus to score samples within the gene 
set. Additional details of rgsepd are presented below. 
3.3 Methods 
 
 The package rgsepd performs several steps in an automated fashion, producing 
many files for later browsing. The user must first provide a matrix of read counts or 
integer gene expression values analogous to read counts at RefSeq identified transcripts, 
as they would to any RNA-Seq statistical analysis package. A second small matrix 
annotates which samples belong to which class, and which classes the user intends to 
contrast. The first automation step is gene expression quantification normalization, leading 
to differential expression. DESeq2 [92] performs the differential expression test at each 
transcript ID#, and with some cutoff p-value, tens to thousands of genes with linear 
separation are detected.  DESeq2 is a scriptable Bioconductor tool designed specifically 
for RNA-Seq data. The gene listing produced by DESeq2 is filtered with customizable 
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parameters for p-value and log-fold-change. Three gene sets (upregulated, downregulated, 
and the union) are analyzed for functional categories.   
Programming using the statistical programming environment R [93] ensures cross-
platform availability, and the open-source nature helps ensure longevity and 
reproducibility. To use rgsepd, input should be formatted as a matrix, with RefSeq NM 
(gene transcript) ID numbers as rows, and sample identifiers as column names. A second 
matrix of metadata links sample identifiers with test conditions and short sample labels. 
GSEPD will automatically compute DEG with default parameters to DESeq2, adjusted if 
necessary for small sample counts [83]. Functional analysis is performed by GOSeq [90], 
once each for downregulated DEGs, upregulated DEGs, and all DEGs.  GOSeq has been 
shown to have similar accuracy to other enrichment toolkits, and robust to gene type 
biases [94].  
GO terms of certain cardinality are evaluated by GSEPD as clusters of samples in 
gene-expression space. The default is to search GO terms with more than one gene and 
less than 31, ensuring precision in the named results, and avoiding the computational costs 
of permuting and calculating in a many-hundred dimensional space. For a GO term with N 
genes each sample can be considered a data point in N-dimensional space, of normalized 
expression (by z-score of log of DESeq2's normalized counts) of the gene. Clustering is 
performed by k-means to achieve recognizable clusters, which are scored by a validity 
measure called V-score [95]. Permuting sample condition labels and re-calculating 
validity computes an empirical significance for each GO term: the segregation p-value. 
The segregating GO terms are evaluated more thoroughly with scatterplots and subspace 
principal components analyses (PCAs). Vector projection is performed within each gene 
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set to score each sample’s similarity to either test-condition centroid, highlighting outliers 
with respect to the subspace. 
3.3.1 Systems Architecture 
The design of GSEPD is a modular pipeline. Figure 3.1 gives an overview, with 
inputs on the left and output on the right. Starting outside GSEPD is data generation at the 
sequencing facility, and user-driven counts-table construction. Details of generating the 
counts table are given in Chapter 4. Along with sample class labels, the dataset is fed into 
GSEPD to perform a pipeline. The first stage is differential expression of the desired 
classes. The results of the differential expression are piped into the functional analysis, 
which could be any functional annotation tool that takes a list of genes and returns a list of 
sets. Finally the projection engine takes in the sets found by the functional annotation and 
the normalized expression table. GSEPD calculates the set-based expression metrics of the 
samples and the segregation statistics for each set. The output is a table of significantly 
segregating sets, and metrics between each sample and each set.  
The design is driven by the motivation in Chapter 2 combined with state of the art 
transcriptome processing. The CNV2012 study revealed the need to accommodate sample 
heterogeneity. The GRN2014 study revealed the need to bring in database driven set 
annotations to reveal useful candidate results. Differential expression and functional 
annotation are commonly used techniques that leave the user with sample-specific 
heterogeneity unexplored. The current implementation of rgsepd takes the sets defined by 
the Gene Ontology Consortium and further evaluates samples’ specific expression by a 
vector projection and a clustering measure.  
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Figure 3.1 Systems Architecture diagram of the components of the GSEPD system, with 
major sections in red outlines. Blue items indicate automated systems. An experiment 
starts at the upper left, with the Sequencing Facility where the tissue samples are 
converted to gene expression quantification through sequencing and processing external to 
GSEPD. The user then creates a table of count data and defines the sample metadata and 
conditions to be compared (lower left, green items indicate user inputs). Across the top are 
External Resources, where functional annotation databases are curated by third parties and 
plug in to the rgsepd software package. The R code wraps subprocesses for differential 
expression, set enrichment, and set based projection scoring. The orange cylinder of 
sample data indicates a normalization produced by DESeq2 with useful expression 
measurements. Within the Projection Engine box are small diagrams of the integral vector 
projections and clustering analyses.  
 
 
 
 
Specifically the differential expression tool used in the current version of rgsepd is 
DESeq2. The differential expression tool could be replaced in other contexts. The 
functional annotation stage uses GOSeq. GOSeq requires gene level identifiers from one 
of several gene name databases. DESeq2 operates on transcripts and is therefore not 
perfectly compatible with GOSeq. A conversion step in rgsepd maps RefSeq transcript 
IDs into Entrez Gene IDs using the Bioconductor database org.hs.eg.db and a hash table.  
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3.3.2 Projection of Samples onto Differential Axes 
The unique final stage of GSEPD is a merging of gene expression values with the 
gene set enrichment results via a novel spatial projection. Vector projection is a 
mathematical tool central to GSEPD’s ability to report set-based clustering. Each 
significantly over-represented gene set reported by GOSeq must have some DEGs, so 
samples of each condition are expected to cluster in the N-dimensional expression space 
(where N is the number of genes in a GO-Term defined set). If the non-differential genes 
within the set have high variability or otherwise significantly outnumber the differential 
genes, the clustering will be poor or not visible. In any case, an N-dimensional line can be 
drawn through the class centroids, and each sample scored for its position along and 
distance to the line. Classes are tested by permuted k-means for significant segregation 
within the gene set. To normalize gene expression between high and low-expressed, genes 
are scaled to a mean of zero and standard deviation of one, after a log-scale reduces the 
dispersion common to RNA-Seq. The projection is a linear transformation (illustrated in 
Figure 3.2) of one vector onto another such that we can calculate a proportionality 
constant and an angle. We need to only define a reference vector, and any point in the 
space can be projected upon it and the proportionality constant (Alpha) is calculated. The 
projection action generates a 1-dimensional measure of position along one vector. 
Therefore with a suitably defined axis, any point can be scored as closer to class A or 
closer to class B.   
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Figure 3.2 Vector Projection Illustration. With the origin at the cross, vector AP is 
projected onto vector AB, yielding the green projection. In GSEPD, the point A is the 
centroid of class A, and point B is the centroid of class B. Point P is any one sample. 
 
 
Consider for example contrasting samples of class A versus class B as shown in 
Figure 3.2. RNA-Seq read count data can be seen as high-dimensional points in Cartesian 
coordinates, with a dimension for each gene's expression magnitude. An ideal dataset is 
represented by NA+NB points in R
(NA+NB). If any genes segregate the samples, they can be 
detected by testing each individually. While performing the projection, GSEPD shifts the 
coordinate system so the centroid of sample class A is at the origin (Figure 3.2).  The end 
of vector AB is the centroid of the class B samples. This new axis from the origin and 
along vector AB represents a linear direction that defined class B relative to class A’s 
centroid. One sample represented by point P lies off the axis and represents a sample we 
want to score along the major axis. In this example, the dimensions are gene expressions 
of each gene in a given gene set. The vector projection scores a sample along the black 
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axis. The green vector and its length, here about two-thirds of the way to B, represents the 
amount sample P is like class B. The ‘Alpha’ score for this sample would be about 0.66.  
The ‘Beta’ score is contained in the black vector perpendicular to vector AB. Beta values 
indicate the distance between a sample and the closest point on the axis. If a beta value is 
high (scaled z-score greater than a configurable threshold) the sample is considered an 
outlier with respect to the class A-B axis for the given gene set. Each gene set is evaluated 
separately, so we generate scorings from samples to gene sets, with most of class A nearly 
alpha=0, and most of class B nearly alpha=1, by construction. 
A schematic drawing with several points in each cluster is shown in Figure 3.3. 
Every gene set found significant by GOSeq is evaluated with an axis and sample-
projections, creating an alpha and beta score for each sample and GO Term pair.  By 
construction of the mean-centroid, roughly half of the samples in class A will have alpha 
scores below zero, and roughly half of those in class B will have scores over 1. The 
distances to the axis are known to scale with dimensionality, and are thus z-score 
normalized before further processing.  
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Figure 3.3 Axis Projection Illustration. Small circles represent samples, X represents the 
samples’ centroid for each class.  The separation along the condition axis is transformed 
such that alpha=0(green) at the centroid of the reference condition, and alpha=1(red) at the 
centroid of the test condition. By extending the colors past the centroids, samples that are 
hyperactivated will keep the brightest color. The beta score denotes deviation from the 
axis and is necessary to retain information that a sample may be like one condition in 
some genes and not others. 
 
 
Every gene set has a one-dimensional scoring, and the clustering accuracy can be 
evaluated. Evaluation of clustering accuracy enables prioritized reporting of gene sets that 
segregate class A and B regardless of dimensionality. As gene sets were chosen from the 
DEG list, some dimensions (genes) must be segregating. The projection process can 
identify genes that may not have been on the DEG list, but help segregate the sample 
classes when taken together with a gene set.  
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3.3.3 Validity Scores Evaluate Clusters 
Many methods exist to measure the goodness of a data clustering, see [96, 97] for 
two reviews of data clustering metrics. “Validity” (V-score) was chosen to incorporate 
specificity and sensitivity within a 0-1 scale, where 1 implies a 100% association between 
class label and cluster label.  The V-score is an external index consisting of the harmonic 
mean of entropic homogeneity and completeness based on the conditional entropy of each 
cluster, given a gold-standard [95].  Given the ‘correct’ class labels, it measures how 
accurate the proposed labeling is. Regardless of the gene set projection score, we can 
calculate how well the gene set's multidimensional expression values in z-log space cluster 
with k-means versus their class labels. A perfect score indicates the gene set really does 
segregate the samples, while noisy or mislabeled samples could induce a lower V-score 
and still show significantly good validity by permuted class labels.  
3.3.4 Clustering Significance by Permutation  
To evaluate the significance of a clustering or association in the presence of 
sample non-independence and measurement noise, careful analysis is required. 
Significance of each association (differential gene usage and overrepresentation of 
ontology terms) is computed by their respective tools.  The novel subspace projection is a 
consequence of the multidimensional expression; what we have to show significance of is 
the segregation of samples. Segregation significance could be computed with linear 
discriminant analysis if sample count were higher than dimension count. When dimension 
count is independent of- or larger than sample count, another significance analysis is 
required. I use a simple Euclidean-distance clustering to find two clusters in the data, then 
compute its agreement with the given class labels via V-score. 
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 K-means is a method that identifies the centroids and assigns sample to either 
cluster using a distance metric [98]. The k-means is performed without knowledge of class 
labels: they are the external gold-standard to measure validity compared to randomized 
labels given the deterministic expression clustering. The k-means resulting cluster can be 
evaluated by computing its “validity” with respect to the known sample classes [95]. The 
V-score ranges from -1 (wrong assignments completely) to +1, (correct assignments 
completely). With every sample assigned to a cluster, the correlation of this assignment to 
each sample’s class is calculated. To compute an empirical p-value I use random 
permutation: computing validity of the k-means clustering after repeatedly assigning 
samples to random classes. The p-value is the proportion of random assignments that 
achieve a higher V-score. A clustering is thereby evaluated in the context of the natural 
variability of the gene set.  
To estimate how many iterations are necessary for precision of the p-value, 
GSEPD evaluates a dynamic denominator. Initially 100 runs are explored and more only if 
there appears a chance for significance (preliminary p<50/100.) The minimum calculable 
p-value is an input parameter P.  At least 1/P permutations would be required, and 
maximally 4/P random permutations are undertaken per GO term to ensure p-value 
precision. In many instances of complete segregation, this yields a p=0 call.    
Measuring Euclidean distance from each point to the class centroids provides a 
final analysis of clustering. Illustrated in Figure 3.4, called Gamma scores, as they come 
after the Alpha and Beta of Figure 3.3.  An alternative to the axis/projection scoring, 
another 2xNxM Gamma scores are generated noting how close each of N points are to 
each of 2 centroids, across M gene sets. The distances are scaled by the dimensionality, 
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such that the centroids are 1 unit apart in all gene sets. The coloring threshold is calibrated 
to assign complete indeterminance to just 10% of the center of the axis between centroids, 
ergo 45% of the line is green and another 45% is red. The absolute value of the distance 
between a sample and a centroid is scaled with the square root of the dimensionality to 
match the Euclidean distance formula. These color values go into hierarchical clustering 
for visual review of the significantly segregating gene sets, while the raw gamma scores 
are reported in two tables (not shown here, see Appendix A for a description of all tables 
generated by rgsepd).    
3.4 Results 
  
A run of rgsepd produces several principal components analyses figures, heatmaps 
of gene expression for DEGs, and tables of all output. All thresholds and parameters are 
configurable before runtime, and configurable output folders and formulaic file naming 
conventions ensure easy reproducibility or automated parameter sweeps. A tutorial and 
explanation of all outputs is available within the package vignette/manuals.  A full run, 
from input of a numeric matrix, to completed functional results is achievable in minutes, 
comparing favorably to weeks of manual processing without an automated pipeline.  
I have run rgsepd on a time series dataset (five time points with two replicates) 
along the differentiation of H1ESC cells into cardiomyocytes (heart muscle cells) [99]. 
We performed RNA-Seq on a time series following duplicate stem cells being developed 
into heart muscle. This dataset is explored in Chapter 4. The raw data have been made 
publicly available at the NCBI SRA (accession number SRP048993). 
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Figure 3.4 Illustration of Gamma Scoring. A simplification of the Alpha/Beta scoring, 
the Gamma score notes Euclidian distance in gene expression space. The results are 
colored with the Euclidean distance to each class centroid.  Samples of class A are drawn 
as squares (class B: circles) in this simulated two-gene set.  The distance is thresholded to 
bright and faded red and green, such that points away from either cluster become gray. 
This scatterplot diagram is not automatically produced in an rgsepd run, as the true gene 
sets are often more than 2-dimensional.  
 
 
Pairwise comparison of all time points revealed that time points day 3 and day 5 
had the fewest differentially expressed genes (3279 HGNC names with p<0.05, 
comprising 2214 GO terms with p<0.05, 1073 of which were found to significantly 
cluster). A feature of GSEPD is the clustering and comparison of non-tested samples 
(here, time points other than day 3 and day 5) with regard to the GO terms that can 
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differentiate test samples (such as point P in Figure 3.2). Incorporation of non-tested 
samples can help researchers label unclassified/indeterminate samples by their expression 
profiles among GO terms relevant to the experiment. 
3.4.1 Processing Pipeline 
DESeq2 computes differential expression from sequence-count data, precisely 
modeling the dispersion present in RNA-Seq [83]. While usage of DESeq2 is 
straightforward for a trained practitioner, this training can be costly or time consuming. 
rgsepd wraps usage of DESeq2 to fully automate the simple case/control comparison 
method.  
Gene Ontology enrichment can be performed in many ways, the most common 
being a hypergeometric test for over-representation of a set within the DEG. GOSeq is a 
readily available (Bioconductor [91]) software package in the R environment that 
performs these tests while controlling for selection biases from sequencing genes of varied 
length. GOSeq is a tool for calculating GO term presence among a gene set with binary 
inclusion criteria, particularly differential gene expression results [90]. I incorporate basic 
usage of GOSeq for the human genome (hg19, refSeq) as part of the pipeline. 
Two sets of projection measure are computed for each gene set. The “HMA” 
heatmaps (example in Figure 3.5) show the distribution along an Alpha and Beta axes 
(defined as Figure 3.3), such that samples can be visualized as how much like either class 
they behave with respect to the direct line between centroids. HMA stands for heatmap-
alpha score. The class centroids are always rescaled to be at vector 0 and vector 1.  
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Figure 3.5 GSEPD Results from the H1ESC Study. The H1ESC dataset of Chapter 4 
is evaluated with GSEPD’s Alpha/Beta heatmap (HMA figure). Notes along the bottom 
are a coded sample identifier ending in the time point name D3 for day 3, D1 for day 1, 
and so on. This figure shows GO terms with significant segregation between day 3 (green) 
and day 5 (red). rgsepd was instructed via input parameter to display only the top 8 
results. The color bar across the top indicates which samples were part of the DESeq2 
contrast, here day 3 in green versus day 5 in red, with black denoting non-tested samples.  
 
 
 
 
To demonstrate potential findings, I present an analysis of the H1ESC data. Six 
time points, named day 0 through day 14 (in duplicate) are seen in the final rgsepd result 
in Figure 3.5. This analysis compared samples of day 3 and 5, which is a critical turning 
point between early tissue development and heart muscle precursors [99]. Each sample has 
a unique ID noted along the bottom of the figure that is relevant for the user, but not our 
discussion of the tool. These have suffixes like T4 and I6 corresponding to Tube#4 and 
Index#6, which were meaningful to the lab performing RNA extraction from the samples. 
52 
Many gene sets were found to perfectly segregate due to the sample’s cloned nature 
boosting significance of the differential gene expression. Here rgsepd’s parameters were 
tuned to yield the eight most significant gene sets. An example result is presented in 
Figure 3.5. Regarding the fourth row “cardiac atrium morphogenesis,” day 3 is unique 
(bright green), day 0 and day 1 have expression near the center of the Alpha axis (faded 
gray) with samples of class day 1 more similar to samples of class day 3, while the 
samples from later days expressing like the samples of class day 5 (red). 
The GSEPD projection Alpha scoring suggests in a data-driven manner that day 3 
was the turning point for the stem cells’ lineage specification. The next two rows show 
that day 3 was unique in “mesodermal cell fate specification” and “commitment”, 
suggesting a unique spike of gene activation that deactivated on all other time points. With 
no biological systems background knowledge, the user of GSEPD can thus extract 
pathway activation knowledge from RNA-Seq count data.  
Within the “cardiac atrium morphogenesis” gene set on row 4 of Figure 3.5, 12 of 
28 genes were found differentially expressed (GOSeq p<2x10-6). GSEPD extracts 
significant gene sets into multi-page scatterplots, one of which is excerpted into Figure 
3.6. The example scatterplot consists of 14 pages of two genes each, showing orthogonal 
views on the 28-dimensional clusters, here PITX2 is shown downregulated in class day 3 
(green) versus class day 5 (red), with gene NOTCH1 upregulated by 1.5 units of logged, 
normalized counts. Colored lines (corresponding to cells of the heatmap of Figure 3.5) are 
perpendicular to the thick black axis in the 28-dimensional space, indicating samples of 
class day 0 and samples of class day 1 fall between the clusters of samples in class day 3 
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and samples of class day 5, although they will not appear perpendicular in this two-gene 
subspace.  
 
 
Figure 3.6 Scatterplot of Two Genes. Corresponding to the seventh row of Figure 3.5: 
(gene set ‘atrial cardiac muscle tissue development’) this diagram is one part of generated 
file GSEPD.D3x2.D5x2.GO0003209.pdf (first two genes). Points as triangles, circles, and 
crosses correspond to the input samples. Solid dots indicate the projection coordinate. 
Labels D5x2 and D3x2 indicate class centroids of the comparison of two samples of day 5 
versus two samples of day 3. The small point labels are specified by the user as each 
sample’s “shortname,” a parameter given to rgsepd.  
 
 
Samples could be scored by distance to each class centroid (Figures 3.4 and 3.7) 
instead of using location along a constructed axis. The magnitude of the distance between 
a sample and either cluster centroid can divide the color into five bins: bright and faded 
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green, medium, and then faded and bright red. Distance is computed as Euclidean distance 
to each class centroid in the n-gene dimensional subspace (scaled by a factor of the square 
root of the dimensionality, such that centroids remain one unit apart). The center 10% of 
the axis is given the medium-gray color, with the ends colored as the sample classes. The 
45% closest to class A is green and the 45% closest to class B is red.  The first two-thirds 
of each color section is denoted ‘bright’ and the latter third ‘faded’ (Figure 3.4).  
 
 
 
Figure 3.7 Gamma Scores Recolor. Example data from the H1ESC, the same analysis as 
seen in Figure 3.5, alternatively visualized by Gamma scores to simplify axis-scoring into 
a single dimension from green to red. Less variation is visible, as we here color gray any 
sample that is more than 0.45 units distant from either class centroid. The coloring is as 
illustrated in Figure 3.4. The color bar across the top indicates which samples were part of 
the DESeq2 contrast, here day 3 in green versus day 5 in red, with black denoting non-
tested samples.  
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The Gamma color scheme simplifies the interpretation of the result in that green 
samples can be said to express like the centroid of class A without reservations. As many 
points may be off-axis in a high dimensional space, the Gamma coloring scheme yields 
many more gray samples (Figure 3.7) than the Alpha/Beta scheme (Figure 3.5). While 
containing the same rows and columns, the hierarchical clustering imposed on the 
heatmap is based on the color-scores so row and column ordering will differ in the two 
output figures of each run. 
 
3.4.4 The Bioconductor Package rgsepd 
A curated catalog of software accompanied by manuals and tutorials is important 
for consistent advancement of computational research.  The Bioconductor project [91] is 
a repository of bioinformatics tools for the R programming language with strict 
guidelines regarding usability and availability. An implementation of GSEPD is 
submitted as an R package “rgsepd” to Bioconductor. Version 1.5.2, which is discussed 
in this dissertation, is freely available in Bioconductor 3.3.  rgsepd version 1.5.2 relies on 
the following R packages: DESeq2, GOSeq, GO.db, and org.Hs.eg.db.  As of July 2016, 
there have been 2,190 downloads of the various rgsepd releases. 
3.4.5 Systematic Output Files 
All files generated by a run of rgsepd are named in the pattern 
TOOL.YYY.AxNa.BxNb.csv, where YYY represents the file type, A and B the class 
labels relevant to the table, and N(a/b) the number of samples in each class. This naming 
convention highlights the conditions and keeps multiple comparisons organized.  
“TOOL” may be DESEQ, GOSEQ, or GSEPD, depending on the data source. In the 
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event the user’s sample conditions have an “x” in their name, creating ambiguity in this 
structure, the delimiter is configurable. Appendix A lists these tables in chronological 
order through a run of the tool, as each result builds upon the previous. In total, 15 tables 
and 11 types of figures are generated in a run. As each interesting GO term may generate 
several figures, a subfolder is created and files are named with the GO ID number to 
enable quickly finding the relevant figures. Producing all result files as CSV or PDF 
permits sharing of results between collaborators. 
3.4.6 Software Limitations 
The current version of rgsepd requires a particular human genome reference data 
format for input tables. Genes must be quantified against a RefSeq transcriptome 
definition. This limitation is due to the rigidity of the automatic gene name conversion 
routines built in to rgsepd. Further software development could enable other species such 
as mouse or plant studies.  Additionally, data input is currently restricted to RNA-Seq due 
to the choice of DESeq2 as the DEG stage (Figure 3.1). Accommodation of other input 
data formats is possible. DEG calculations are restricted by the user interface to a two-
class contrast experimental design.  
The projection and clustering stages assume absolute valued expression data not 
compatible with florescence based microarray technologies. Gene set results coming 
from relative expression platforms will require further experimentation and validation. 
Count-based data are ideal, such that rgsepd would more easily be adapted to sequencing 
based assays.  
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3.5 Conclusion 
 
This chapter has outlined transcriptomics as a tool for exploration of biological 
processes, and has presented a software toolkit to facilitate those analyses.  Application to 
two data sets is shown in Chapter 4, highlighting the uniqueness of findings possible 
with GSEPD.  The Bioconductor package has been under development and is publicly 
available and as per their guidelines includes considerable manuals and tutorials. The 
package tutorials are included with the software download. It is my sincere hope that this 
free and open source tool can facilitate many third party research groups that have 
struggled with transcriptomics and data interpretation in the past.  
  
The rgsepd toolkit is available for public use at the website 
http://www.bioconductor.org/packages/devel/bioc/html/rgsepd.html 
See Appendix A for a complete description of the generated output files.  
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CHAPTER 4  
APPLICATION TO TWO HEART DEVELOPMENT STUDIES 
 
To show their merit, findings and methods from previous chapters are applied to 
several important clinical situations.  Specifically, I present two instances where 
application of the toolkit from Chapter 3 implementing the insights of Chapter 2 to an 
open problem in cell biology are able to validate and expand upon the findings of an 
expert in the field of heart development [99, 100]. In each of two case studies I present 
the original manual findings, then the results that could have been found by GSEA [88], 
then finally the results that could have been found using GSEPD.  
4.1 H1ESC Differentiation Time Series Functional Analyses 
 
The first case study is referred to as H1ESC: pertaining to a stem-cell study (of 
commercially available type H1E) published in early 2015 in PLoS ONE [99]. In 
collaboration with the Medical College of Wisconsin Department of Molecular and Cell 
Biology, we performed a transcriptome analysis of duplicate samples at six time points.  
The study explored a problem in applied cellular development and refined the best-
known recipe for generating living human heart muscle, which is important for later 
experiments. Following standard protocols, cell culture differentiation has low efficiency: 
many dead cells and failed experiments [101]. The H1ESC study sought to optimize the 
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state of the art in stem cell differentiation by evaluating gene expression throughout the 
differentiation process.  
4.1.1 H1ESC Study Methods 
The H1ESC study [99] was an exploration of recipes (protocols) for growing 
commercially available stem cells into beating heart tissue. Pluripotent stem cell 
differentiation is an expensive task, and a prerequisite to many studies on living human 
cells [102].  The state of the art methods were inefficient, in the sense that many attempts 
failed and retrials required. Our collaborator, Dr. John Lough of the Medical College of 
Wisconsin Department of Cellular and Molecular Biology, had an idea that tweaking the 
recipe would activate growth patterns in a more precise manner. We took transcriptomic 
measures across a time-series of the cells’ growth and saw pathways activating 
sequentially. Time-series information had not been available on this model system, so the 
scientific community did not know the exact timing and level of gene expression on the 
genomic scale for these processes.  
Duplicate samples from each of six time points were collected and RNA was 
extracted as described previously [99]. Samples were sequenced on an Illumina HiSeq 
2000 at the Human and Molecular Genetics Center of The Medical College of Wisconsin, 
and the Illumina CASAVA pipeline produced FASTQ files from the fluorescence data. 
Sequence data were processed with RSEM into a measure of transcripts per million 
mapped (TPM) [103]. RSEM uses Bowtie’s unspliced mode [73] onto a reference 
transcriptome of 38,653 sequences. A data matrix was compiled in R consisting of 6 
columns (samples) and 38,653 rows (gene transcripts.)  Genes were selected by the 
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domain expert by colloquial name, and converted to transcript IDs by selecting the 
highest average expression when more than one transcript were present.  
4.1.2 H1ESC Study Results 
The H1ESC study explored gene expression on an ad-hoc basis. Genes known to 
be relevant for the biological process were reviewed. Figure 2 of that study, here 
excerpted into Figure 4.1, shows three biological pathways. From day 1 to day 3 for 
example we see the precipitous increase of “pan-mesoderm” profiles and “early 
cardiomyogenesis signaling”. We learned a sequential gene activation (FGFR series) 
indicated a possible optimization. The differentiation protocol was modified, and we 
achieved an increase in cell survival, implying lower cost, and enabling more 
experiments [99]. With the transcriptome measures at tens of thousands of genes, we 
relied on experts to identify a handful of important genes, and their categorization.  
 
4.2.3 H1ESC Study GSEA 
To go beyond a manual annotation of functional sets, one could use GSEA on the 
H1ESC dataset. The data matrix originally containing 38,653 transcript identifiers is not 
compatible with GSEA, and these can be converted to 23,099 named genes for use with 
GSEA’s gene symbol annotations. The Bioconductor package org.hs.eg.db was used to 
convert gene names and included non-gene LINC and MIR elements. GSEA requires a 
selection of a gene set collection; c5.all.v5.1.symbols.gmt was used to select an up to 
date Gene Ontology set, containing 1,454 gene sets. Analysis was restricted to sets under 
31 genes each to ensure comparable results with rgsepd’s default parameters. 801 gene 
sets passed the set size filter. GSEA supports simple two class comparisons and ignores 
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other samples in the data file. Comparing days 1 and 3 consists of a 2 sample versus 2 
sample test, which is below the minimum required for the default gene expression 
analysis method “Signal2Noise.” Processing was completed under the “Diff of classes” 
scheme, wherein all genes are ranked by the absolute difference in the means between 
comparison classes.  
 
 
 
Figure 4.1 Excerpt of Figure 2 of the H1ESC Study, cropped to show annotations of 
three gene groups. Time points are marked along the bottom, in days post pluripotency 
induction. The color corresponds to the z-score of the log of the expression, such that 
high absolute expression for each gene is shown in red, and low in green. Black 
represents mean (or baseline) expression. Unique to a sequencing based assay, we also 
annotate absolute gene expression in each cell (black text, units are ‘transcripts per 
million’ [103]).  
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Using the ranked list of 23,099 genes, GSEA reports separate lists of sets found 
upregulated in each comparison class. Eighty-two gene sets were found significantly 
enriched and upregulated among day 1 samples, and zero were found among day 3 (both 
p<0.05). The top ten sets from comparing day 1 and 3 are listed in Table 4.1. The most 
significant set was “epithelial to mesenchymal transition,” which is expected in this 
context. The tenth being “muscle cell differentiation” is a good indicator that the samples 
are doing what we wanted them to. GSEA provides no sample-to-set scores at this high 
level, but drilling into each category shows a separate gene-level heatmap of expression 
of the four samples involved in the comparison.  
 
 
NAME	 ES	
NOM		
p-val	
FDR	
q-val	
EPITHELIAL_TO_MESENCHYMAL_TRANSITION	 0.87	 2.08E-03	 0.194	
CALCIUM_INDEPENDENT_CELL_CELL_ADHESION	 0.74	 0.00E+00	 0.270	
INWARD_RECTIFIER_POTASSIUM_CHANNEL_ACTIVITY	 0.81	 2.04E-03	 0.271	
MYOBLAST_DIFFERENTIATION	 0.78	 1.00E-03	 0.272	
NEUROPEPTIDE_RECEPTOR_ACTIVITY	 0.74	 0.00E+00	 0.287	
SARCOMERE	 0.76	 4.04E-03	 0.289	
NEUROPEPTIDE_BINDING	 0.73	 0.00E+00	 0.292	
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS	 0.75	 1.11E-02	 0.300	
INTEGRIN_COMPLEX	 0.73	 4.00E-03	 0.304	
MUSCLE_CELL_DIFFERENTIATION	 0.73	 1.00E-03	 0.305	
Table 4.1 H1ESC Study GSEA Results. Top ten sets from the comparison of day 1 
versus day 3. Four columns extracted from the GSEA report correspond to the set’s 
identifier, the enrichment score, the nominal p-value, and the false discovery rate 
adjusted significance.  
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4.2.4 H1ESC Study GSEPD 
Running rgsepd on the read data generated by RNA-Seq and RSEM, any two 
classes can be contrasted in depth. Starting from count data at 38,653 gene transcripts, 
4,640 were identified as significantly changing between samples of class day 1 and day 3. 
For this run, rgsepd was configured to require p<0.01 to consider individual genes 
differentially expressed, thereby yielding a more precise and conservative result set than 
if the traditional threshold of p<0.05 was used. The functional annotation segment of the 
pipeline finds 3,720 GO terms enriched p<0.05. The projections and segregation analyses 
evaluated sets passing gene count filters, and found 1,050 sets to significantly segregate 
samples of day 1 from samples of day 3.  
GSEPD produces the GO term based heatmap, seven rows of which are shown in 
Figure 4.2 (from the generated file GSEPD.HMA.D1x2.D3x2.pdf), with twelve samples 
displayed. Day 0 being green indicates its similarity to the comparison class day 1 with 
respect to the gene sets shown. As mentioned in Chapter 3, showing the position of non-
tested samples like day 5 can be informative to give context to the otherwise high 
dimensional data. It is validating, informative, and potentially hypothesis-generating for 
the researchers of this study to see samples of class day 5 being more like samples of 
class day 3 than samples of class day 1 in the first gene set: mesenchyme morphogenesis, 
as this was a mesenchymal development protocol. Overall, day 8 and day 14 samples 
being more like day 3 samples indicates a linear sequential development, wherein, with 
respect to the functional sets that changed between day 1 to day 3, later stages share more 
in common with the later time point.  
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Figure 4.2 Excerpt from the GSEPD Result’s HMA comparing day 1 to day 3. The 
colored bar along the top notes the comparison samples’ class labels. Sample classes are 
listed along the bottom. Rows and Columns are ordered by a hierarchical clustering such 
that similar samples are adjacent. 
 
 
To take a broader view, unbiased by an individual’s interest in each gene, we can 
perform GSEPD on sequential time-points to identify the broader processes at work. 
GSEPD identified “mesenchyme morphogenesis” at the top of the Figure 4.2. In the 
textual result (Table 4.2), many pathways were identified as completely segregating the 
conditions. The third row of Table 4.2 is an extremely precise “cell surface receptor 
signaling pathway involved in heart development” with 14 genes differentially expressed 
(of 24 total).  Six of the 16 genes on Figure 4.1 are “cell surface receptors” (FGFR1, 
FGFR2, FGFR3, BMPR1A, BMPR1B, and BMPR2). The GSEPD tool is validated by 
identifying the same activities an expert would identify.  
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GO ID GOSeq P 
Differentially 
Expressed 
Genes 
Genes 
in Set GO Term 
GO:0003197 5.49E-11 16 27 endocardial cushion development 
GO:0071294 4.99E-10 9 13 cellular response to zinc ion 
GO:0061311 1.26E-09 14 24 
cell surface receptor signaling 
pathway involved in heart 
development 
GO:0072132 6.71E-09 15 30 mesenchyme morphogenesis 
GO:2000826 6.98E-09 14 27 regulation of heart morphogenesis 
Table 4.2 H1ESC Study GSEPD Results. Top five rows by significance, from 
generated table GSEPD.HMA.D1x2.D3x2.csv.  These pathways are identified in the 
comparison of day 1 versus day 3 with GSEPD. The columns correspond to gene set ID, 
GOSeq significance, number of genes found differentially expressed, the number of 
genes in the set, and the set’s name. These results are sorted by GOSeq p-value, because 
all sets were found to have equivalent 100% segregation due to low sample variability.  
 
 
We also find many unexpected gene sets with similar evidence levels. In Table 
4.2, second after “GO:endocardial cushion development”, GSEPD finds “GO:cellular 
response to zinc ion” with 9 genes differentially expressed of 13 in the GO term (9/13 
DE).  The cellular sample system seems to be in a known response pattern to zinc ions, 
which may lead to an extension of this heart development pathway in further research. 
 Along the right of Figure 4.1 are manual annotations of gene sets. They are 
recapitulated by GSEPD in a completely database driven manner, bypassing any 
individual’s preconceptions. GSEPD’s ability to quickly identify biologically relevant 
pathway perturbations from transcriptome data enables faster research and unexpected 
findings.  
Four key genes are highlighted as “Bmp signaling” near the bottom of Figure 4.1. 
GSEPD reports “response to BMP” with 13/22 genes DE (data not shown). The top of 
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Figure 4.1 is a group of manually annotated genes under the heading “Fgf signaling”. 
GSEPD reports “type 2 fibroblast growth factor receptor binding” with 4/4 genes DE at 
p<10-4. The middle category, “pan-mesoderm/early cardiomyogenesis” is seen as 
GSEPD’s fifth-most significant set, “regulation of heart morphogenesis“ at 14/27 genes 
DE for p<10-8 (Table 4.2). These 14 identified genes go beyond the three known markers 
represented in the H1ESC publication. Two other interesting results, at 7/9 genes DE 
identified are “neurofilament” and “cell migration involved in heart development” in 
completely disjoint sets.  Specifically, between day 1 and day 3 GSEPD identified 1050 
GO terms (37 after Bonferroni correction).  The segregation scores are maxed-out at 
100% due to the small sample of two versus two cloned samples.  
With GSEPD I propose we can discover new connections, by harnessing entire 
databases and presenting systems biology level results in a compact and convenient 
manner. For example, a novel and unexpected finding is the second row of Table 4.2, 
“cellular response to zinc ion”.  The word zinc appears nowhere in the publication. 
Opening the results file GSEPD.RES.D1x2.D3x2.GO2.csv reveals all genes and how 
each gene’s expression changed underlying each GO term. It lists 13 genes under the 
“cellular response to zinc ion” heading GO:0071294, here included as Table 4.3.  The 
GO2 file (as described in Appendix A) collects mean expression in each class (here 
testing day 1 versus day 3), the test statistics from the differential analysis, and the 
functional analysis statistics as a cross-product. The GO2 file allows a simple 
spreadsheet search function to extract the computed metrics of each gene within the 
identified GO term. Neither DESeq2 nor GOSeq could provide the combined product. 
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Quick retrieval of the gene-based evidence underlying each GO term result is a marked 
functional advancement for the biomedical end-user. 
 
 
Gene D1x2 D3x2 PADJ Gene D1x2 D3x2 PADJ 
CREB1 10.1 10.2 7.13E-01 HVCN1 8.81 11.7 4.50E-12 
MT2A 12.8 8.43 3.05E-43 MT1F 12.3 8.34 1.37E-36 
MT1G 12.2 6.85 1.05E-61 MT1B 6.86 6.66 8.26E-01 
MT1H 10.8 6.58 1.88E-88 TSPO 10 9.97 9.88E-01 
MT1M 9.5 6.49 1.32E-30 MT1E 12.1 7.08 7.51E-95 
MT1A 8.7 6.85 5.14E-11 KCNK3 6.71 6.69 9.88E-01 
MT1X 12.3 8.94 2.22E-43 
	 	 	 	Table 4.3 Subsection of GSEPD.RES.D1x2.D3x2.GO2.csv rows 286,317 through 
286,329. This file includes every moderately significant GO Term and all genes 
underlying each, for the purpose of quickly extracting a genomic profile. Column Gene is 
the HGNC gene name (The Human Genome Organization’s Gene Nomenclature 
Committee is the authority by which genes are given registered identifiers). Column 
D1x2 is the mean expression of the day 1 class, of which there were two samples. Units 
are from DESeq2, as a variance-stabilized and log2-normalized read count of the original 
RNA-Seq, such that 11 is approximately twice the expression of 10. Column D3x2 is the 
day 3 class mean. Column PADJ is the multiple-testing corrected p-value from the 
DESeq2 test for differential expression between those classes. This section of the larger 
listing corresponds to only those genes that are a part of GO:0071294. 
 
 
 
 
 The GSEPD results shown in Table 4.3 note the expression of genes underlying 
“cellular response to zinc ion.” Nine of 13 genes are highly significant with 8 reducing 
between day 1 to day 3, one gene increased (HVCN1 from 8.8 units to 11.7), and four 
unchanged.  Metallothioneins 1G, 1H, 1M, 2A, and 1A drop precipitously between the 
time points, while HVCN1 activates. A zinc-related finding was unexpected and would 
have gone unnoticed without GSEPD’s merging of gene and gene set based results.  A 
simpler functional annotation tool would bury the interesting results: the GSEPD 
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intermediary step GOSeq found 1,894 gene sets overrepresented (p<0.01) in the day 1 
versus day 3 differential expression analysis.  
4.2 Genetic/Mechanistic Link in A Congenital Heart Disease 
 
In the second study of this chapter I demonstrate that GSEPD is useful in 
identifying relevant molecular pathways (gene sets) when sample classes are human 
disease risk factors.  
4.2.1 MYH6 Study Methods 
In 2015 we completed a clinical association study known as MYH6, for the gene 
identified therein, known to be vital for muscle contraction [100]. In the MYH6 study, we 
started with the genomes of a family with a particular CHD, explored a population with 
the same disease and made a case for the role of MYH6 in that CHD subtype.  This 
particular CHD subtype is present in the fetus, and fatal before adulthood [104], 
precluding high penetrance causes from permeating the population, therefore this 
mutation has not been thoroughly explored by the medical community.  
The genomes of a nuclear family were compared to databases of mutational 
significance, and a short list of possibly causal genes was developed. We then looked at a 
population of 190 other patients and evaluated each of the possibly causal genes for 
occurrence frequency in a case/control analysis. We then contrasted tissue transcriptomes 
of carriers and non-carriers for MYH6 variants to find what we call the compensatory 
pathway: the body’s natural response to the mutation.  
The MYH6 study explores the transcriptome of several samples of heart tissue. 
Sequence data collection and processing was as described in section 4.1.1. Because the 
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transcriptomes were predominantly divided by their subject’s age and tissue type, the 
more subtle profiles could be lost to noise [105]. To ensure cleaner results, we used a 
paired test, which limits the available data to those with suitable carrier/non-carrier 
samples of matched subject age and tissue type. Samples were labeled WV and WR, for 
those with variant and those with the reference allele. A paired test controls for covariates 
and yields a short list of genes. We used edgeR [81] with a factor covariate indicating 
manually identified sample pairs.  Criteria for significance was set at p<0.05, effect size 
absolute log2 difference > 1, and high average expression (defined here as logCPM > 6).  
4.2.2 MYH6 Study Results 
Twenty-four gene transcripts were both highly expressed and significantly 
perturbed (Table 4.4). MYH7 was immediately recognized as a gene homologue to 
MYH6 (sharing >95% sequence similarity.) Upregulation of MYH7 is filling the role of a 
defunct MYH6. The compensatory pathway for MYH6 (a muscle contractile protein) 
seems to be elevated expression of several other genes related to muscle contraction. 
Other findings, such as the EEF and RPL families are possibly the pathway the body uses 
to select or regulate the proteins used by cardiac cells.  
4.2.3 MYH6 Study GSEA 
The sample data of the paired analysis can be processed with GSEA. GSEA 
performs two class contrast analyses, designed for microarray chips, but suitable for other 
transcriptome measures. Parameters to GSEA were set to match GSEPD as closely as 
possible: using the Gene Ontology collection (c5.all.v5.1.symbols.gmt) restricted to gene 
sets of size two to 31 genes. GSEA supports several statistical models. Two class 
comparison was configured to use the “tTest” mode.  
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Gene 
Change 
Among 
Carriers P-Value Gene 
Change 
Among 
Carriers P-Value 
ACTA1 315% 0.0051 MYL2 366% 0.0039 
ALDOA 210% 0.0025 RPL12 45% 0.0086 
COX6A2 250% 0.0070 RPL17 23% 0.0003 
DQ668365 265% 0.0007 RPL21 15% 0.0001 
EEF1A1 36% 0.0033 RPL41 21% 0.0017 
EEF1B2 50% 0.0053 RPL9 28% 0.0012 
EF011072 325% 0.0038 RPS26 21% 0.0034 
ENO3 312% 0.0002 RPS27A 36% 0.0003 
H3F3AP4 39% 0.0017 RPS3A 42% 0.0040 
HHATL 241% 0.0026 RPSA 22% 0.0007 
HNRNPA1 46% 0.0015 TNNT2 1231% 0.0028 
MYH7 346% 0.0007 TPM2 221% 0.0009 
Table 4.4 MYH6 Study Paired Test. Twenty-four significant gene level changes were 
found in the carrier versus non-carrier test [100]. The DEG group into twelve identifiable 
gene families. Two sets of 3 columns indicate the gene name, effect size, and significance 
computed with edgeR [81].  
 
 
 
 
The dataset originally contained 38,653 transcripts, and was collapsed to 23,099 
named genes to be compatible with the GSEA annotation of GO. Significant sets were 
calculated from the differentially expressed gene list as a ranked object. The output GO 
collection lists 1,454 sets, 801 of which pass the set size filter.  GSEA reports enrichment 
of 34 sets upregulated in phenotype WV and 2 in WR (with nominal p<1%).  Top ten 
significant sets are shown in Table 4.5. GSEA does not score each sample separately for 
any set’s expression profile.  
The third row of Table 4.5 mentions “contractile fiber” and constitutes the 
agreement with the manual process’s indication of a compensatory pathway. The set 
“mitochondrial respiratory chain,” being upregulated in class WV represents an effect 
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that was unnoticed because the genes that make up this set were not part of the 24 
transcripts identified in the MYH6 study.  
 
 
NAME	 ES	
NOM	
p-val	
FDR	
q-val	
MITOCHONDRIAL_RESPIRATORY_CHAIN	 0.71	 0.00E+00	 0.037	
REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION	 0.63	 0.00E+00	 0.050	
CONTRACTILE_FIBER	 0.64	 1.91E-03	 0.056	
HYDROGEN_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY	 0.64	 0.00E+00	 0.061	
RESPIRATORY_CHAIN_COMPLEX_I	 0.73	 0.00E+00	 0.067	
NADH_DEHYDROGENASE_COMPLEX	 0.73	 2.01E-03	 0.073	
CONTRACTILE_FIBER_PART	 0.66	 0.00E+00	 0.079	
GABA_RECEPTOR_ACTIVITY	 0.75	 4.00E-03	 0.094	
PEPTIDYL_TYROSINE_PHOSPHORYLATION	 0.61	 0.00E+00	 0.098	
MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I	 0.73	 0.00E+00	 0.106	
Table 4.5 MYH6 Study GSEA Results. Top ten identified gene sets found by the 
analysis of the MYH6 carrier versus non-carrier differential expression analysis [100] 
with GSEA [88] ranked by q-value. Column ES is the enrichment score, NOM p-val is 
the nominal set significance, FDR q-val is the false-discovery rate adjusted significance.  
 
 
4.2.4 MYH6 Study GSEPD 
GSEPD performs two class contrast analyses where the MYH6 study’s manual 
process used a paired-samples test. To circumvent the experimental design limitation, the 
user may take advantage of rgsepd’s file architecture and insert differential gene 
expression results into the pipeline. Inserting the results of the pairwise differential 
expression analysis (Table S3 of [100] consists of Table 4.4 extended to the whole 
genome) as the differential expression table of GSEPD lets the functional annotation and 
projection components operate on the gene results from a more complicated differential 
expression test. 
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The GSEPD pipeline found 617 gene transcripts to be significantly differentially 
expressed, 422 GO terms upregulated in non-mutant, and 254 GO terms upregulated in 
mutant. Combining the 422 and 254 GO terms and filtering to sets with the requested 
number of genes (2 to 31 by default), GSEPD evaluated 392 sets (139 consisting of up, 
230 down, and 23 with mixed up/down) for segregating ability. Finally GSEPD found 33 
gene sets with significant sample segregation (seven of which are represented in Figure 
4.3). The results include (at rows 4,5, and 6) the muscle contraction pathways found by 
both the manual process and GSEA. The other sets identified by GSEPD are potentially 
therapeutic pathways.  
Unique to GSEPD is a sample-to-set scoring, represented by the colors of Figure 
4.3.  The WV class defines the red expression profile, and the WR class defines the 
green. Two samples are seen to be on the wrong side: MAAA1600-WV and VFY-WR, 
indicating their response to the mutation was inconsistent with the trend discovered in the 
other six pairs of samples at these gene sets. Some differences are expected, as each 
subject had a different form of the mutant gene, and a different familial background. The 
unexpected gene expression measures of samples MAAA1600-WV and VFY-WR open 
up further avenues for experimentation.  
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Figure 4.3 MYH6 Paired Analysis with GSEPD, testing 8 MYH6-mutant tissue 
samples (WV: with variant) against 8 non-mutant (WR: with reference), all sourced from 
the CHD subjects’ explanted tissue. Figure is cropped to show only a few rows of a larger 
result set.  Subject pairing identifiers are noted along the bottom and labeled with WV for 
mutant carrier of a MYH6 variant, or WR for wild-type MYH6. 
  
 
4.3 Summary 
 
In Chapter 4 GSEPD and GSEA were applied to two case studies where the 
domain expert manually annotated function of gene sets found interesting by his or her 
transcriptome experiment. Finding expression patterns of gene sets via manual review is 
a major bottleneck of time and effort. The cost potentially prevents complete data 
exploration. For example, in both case studies the findings were limited to genes 
recognized by the domain expert, while other findings went unreported. GSEPD provided 
a window to browse the high dimensional transcriptome data that has to date been 
opaque. I have shown GSEPD can recapitulate the pathway-based findings, while 
providing a sample-specific gene set analysis. The novel multidimensional projection 
technique employed by GSEPD highlights systems-level patterns on individual samples.  
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In the H1ESC study consecutive time points were not carefully analyzed, in part 
because six time points have fifteen ways to contrast, for which the experimental design 
was underpowered. With GSEPD fifteen configurations are quickly run, and the user may 
sort and rank the results together, or quickly browse each comparison’s result set. In the 
MYH6 study we found one weakly defined pathway that was completely novel, as the 
MYH6 knockdown genotype is unstudied in humans. GSEPD identifies specific pathways 
such as “regulation of muscle filament sliding” or “selenium compound metabolic 
process.” which had gone unnoticed, but are avenues of future research for treatment or 
prevention of human CHD.
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CHAPTER 5 
CONCLUSION 
Computational Sciences is an interdisciplinary research field, aiming to bring the 
tools of data analytics to other domains. While many scientific domains are in need of 
computational support, medical bioinformatics is an exciting avenue supporting 
biomedical research: a field where real advances have the opportunity to save lives.  
5.1 Scales Untenable 
 
Biomedical research, specifically human development and genomics, is in a 
particularly difficult state. Samples are rare or precious, we cannot generate experimental 
tissues of human fetuses, and the samples we do obtain have all the diversity of mankind. 
I see this as an opportunity to deploy computational sciences in support of valuable 
medical research. Human genomes are enormous and so diverse that the next generation 
reference maps are nonlinear graphical models, challenging the paradigms of sequence 
alignment and simple gene comparisons. Medicine needs smarter tools. My research 
work is to create smarter tools that integrate broad knowledgebases such that the 
culmination can be applied in every forthcoming transcriptome analysis.  
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5.2 Complementary Datasets 
 
Careful literature review reveals myriad small scale studies where one or a small 
handful of genes’ usages are explained. Collection of these results is a task outside the 
grasp of any one person. Future tools in AI like IBM Watson are being deployed to scour 
the medical literature. In that theme, the tools developed and methods applied in the 
current work aim to bring together large-scale datasets in the form of public databases, 
which, while ostensibly available, are out of reach for routine annotation on everyday 
analyses. Researchers deserve to have large scale databases brought to them on their 
terms, freely and quickly. A wealth of interaction databases are available, but without 
computational support to annotate their findings, medical researchers are manually 
perusing interesting hits piecemeal. My work has been to collapse and process data into a 
meaningful picture.  My future work is to bring down the barriers with intelligent 
automation, amplifying research results. 
5.3 Transcriptomics 
 
Moving beyond point mutations and DNA rearrangements to gene usage and gene 
set usage will enable future researchers to make more effective use of their precious 
tissue samples. More knowledge could be mined from the same animal experiments or 
human surgical discards. Other high throughput experiment types are being developed 
every year, and they too will need intelligent overviews that GSEPD can provide. 
The methods of Chapter 3 can be applied to other data types. Several other 
sequencing technologies generate genome-wide scores analogous to RNA-Seq’s 
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quantification of transcript activity, such as bisulfite sequencing and methylation specific 
sequencing [106]. These could also be fed into rgsepd. Like with RNA-Seq, epigenetic 
activation is quantification at the gene level, inducing the same kinds of data deluge we 
sought to remedy in Chapter 3. Collection to the GO Term level and clustering with 
validity scores could yield more informative results in those research areas [107]. 
Furthermore, adaptation to non-human experiments is an obvious next step for rgsepd 
version 2. The limited input format of rgsepd is RefSeq human transcript identifiers, but 
more flexible gene name conversion routines would enable any model organism.  
5.4 Applications 
 
In this dissertation I have shown two studies in Chapter 4 where the experts in 
their field have desired to annotate functional significance to their gene-centric analyses. 
Although other tools exist, they are limited in interface and applicability. I have created a 
human transcriptome analyzer in GSEPD that shows inherently high dimensional data as 
a simple colored heatmap: using vector projections to directly calculate how each sample 
behaves like each test condition. I believe set-level expression is the way the end-user-
researcher understands their data, and projection provides the most understandable 
dimension reduction. Finally, Gene Ontology analyses are accessible on a sample-to-
sample level, and I hope to highlight not just the expected pathways, but the many 
annotated results that are currently going unseen in vast databases.  
In the MYH6 study we showed the effects of a mutation in a heart muscle being 
compensated by the living host. GSEPD also predicts impacts on the eosinophils and 
forebrain neurons. These effects would have gone unnoticed, as researchers in neuron 
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development are unlikely to be interested in a cardiac-defect publication. Bringing 
together the online databases is the best way to advance biomedical research at the fastest 
pace possible. The MYH6 study’s variant carriers versus non-carriers analysis of 
Chapter 4 mentioned a selenium metabolism process. An expression profile exists with 
statistically significant segregation ability, indicating a real difference related to the 
MYH6 mutant status. GSEPD indicates selenium is potentially an avenue for treatment, 
wherein a drug dose could influence the gene expression, bringing unhealthy patients 
back in line with the non-carriers. 
GSEPD enables a systems-level evaluation of any test treatment on a cell culture. 
In the H1ESC study we evaluated the effects of Activin-A and BMP dosage on heart 
muscle development. GSEPD could reveal the downstream effects and further streamline 
the differentiation protocol.  A systematic analysis of published data sets like the Illumina 
Bodymap project or The Cancer Genome Atlas would reveal thousands of subtle systems 
level effects that have been obscured behind the dimensionality of the transcriptome. 
The role Computational Science plays to non-computing domains is a role of 
analytical and interpretive support. We have a duty to the scientific community to help 
and advance where the need is greatest.  My work has had impacts in the study of organ 
development [7], treatment of congenital diseases [100], and basic stem cell research 
[99]. rgsepd, as open source software, is freely available to facilitate transcriptome 
analyses around the world [91]. I hope it has a positive impact on many future studies. 
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APPENDIX A 
 
Appendix A is a listing of tables and figures generated during a run of rgsepd. In 
each file/figure/table the filenames are constructed to ensure that the user can find and 
associate the file with the run comparing sample class A with class B.   
A.1 Tables Listing 
 
DESEQ.counts.AxN.BxN.csv - post normalization, sample columns. Tables are 
generated of the normalized counts, produced by DESeq2, but made available in simple 
CSV format. Similar to the input data table, but library scale normalization has been 
computed, so these are ready to visualize for ad-hoc analyses. Corresponds to the orange 
cylinder in Figure 3.1. 
DESEQ.RES.AxN.BxN.csv – Results file from DESeq2, containing transcript ID 
numbers from the input data, and computed statistics for fold-change and p-values. 
DESEQ.RES.AxN.BxN.Annote.csv – annotated version of the previous table. 
After some database calls out to Biomart and Ensemble databases, most transcript ID 
numbers can be associated with a gene name and gene ID number. Here I also annotate 
the sample class means for expression of each transcript/row. This file makes it possible 
for the end user to quickly search a gene name and retrieve simplified expression 
averages. 
DESEQ.RES.AxN.BxN.Annote_Filter.csv filtered version of the previous table. 
Given the constraints of significance presented in advance of a run, a filtered table is 
produced. An rgsepd run culls genes without sufficient change between classes, or 
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sufficient statistical significance, or sufficient absolute expression. These three values are 
configurable if the user needs a shorter or longer table of genes for their experimental 
situation. The filtered list is the basis of the latter stages of functional annotation and 
projection.  
GOSEQ.RES.AxN.BxN.GO.csv – the result of the included GOSeq run. GOSeq 
computes the functional annotation to the filtered gene set by searching for 
“overrepresented” gene sets among the space of all GO Terms in a hierarchy. I run it for 
each of the three major GO trees, then filter the list to nominal significance and annotate 
the results with the English names for each GO Term identifier.  Also included for 
convenient interpretation are the summary statistics “number of genes in GO Term” vs 
“number of genes differentially expressed”. This list contains many large GO Terms and 
filtering to the number of genes can quickly refine to precise biological processes found 
differential between classes “A” and “B”. 
GOSEQ.RES.AxN.BxN.GO-UP.csv is a table similar to the previous overall GO 
listing, but here genes are considered only when upregulated in class A versus class B, as 
the user may be interested in seeing which functional sets are “turned on” in response to 
the condition. 
GOSEQ.RES.AxN.BxN.GO-DOWN.csv is a table similar to the overall GO 
listing, but here genes are considered only when downregulated in class A versus class B, 
as the user may be interested in seeing which functional sets are “turned off” in response 
to the condition. 
GOSEQ.RES.AxN.BxN.GO2.csv is a joint table collecting the genewise 
summary statistics of the DESEQ.RES.AxN.BxN.Annote.csv and copying them onto 
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each significant row of each GOSEQ table. Broad GO Terms will carry redundant data 
with more precise terms, so anything greater than 1000 genes is filtered before this table 
is created. The GO2 file is the largest single entity, with approximately 347 thousand 
rows from the run that produced Figures 3.5-7. Here a gene set can be searched by name 
or key word, the genes identified by name and their average and differential expression 
data readily reviewed or further filtered by the user. This table answers the question 
“what genes are in this gene set?” 
GSEPD.RES.AxN.BxN.MERGE.csv is a filtering and collation of the GOSEQ 
tables. Cropping the GOSEQ.RES.AxN.BxN.GO2.csv to the most significant terms, and 
those below a specified gene-count yields a manageable list of interesting functional 
associations. Each is annotated with “Up”, “Down”, or “Mix” depending on which of the 
three GOSeq runs found the term. 
GSEPD.Alpha.AxN.BxN.csv is a table of Alpha scores, samples on columns by 
GO Terms on rows. Alpha scores are defined in Section 3.3.2 and Figures 3.3 and 3.5.  
GSEPD.Beta.AxN.BxN.csv is a table of Beta scores, samples on columns by GO 
Terms on rows. Beta scores are defined in Section 3.3.2 and Figures 3.3. 
GSEPD.HMG1.AxN.BxN.csv is a table of Gamma1 scores, each sample (on 
columns) by their distance (N-dimensional Euclidean distance to class A’s centroid for a 
gene set of size N) to each GO Term (on rows). These Gamma1 values are defined in 
Section 3.3.4 and used in the coloring scheme of Figures 3.4 and 3.7.  
GSEPD.HMG2.AxN.BxN.csv is a table of Gamma2 scores, similar to Gamma1 
but noting the distance to the class B centroid.  
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GSEPD.Segregation_P.AxN.BxN.csv lists the clustering Validity scores and 
associated p-value for each GO Term. Each gene set is evaluated for clustering validity 
(Section 2.3.3) and an empirical p-value is calculated (Section 2.3.4). This table lists 
those results by GO ID. 
GSEPD.HMA.AxN.BxN.csv with gene set segregation completed, the most valid 
GO Terms are represented in this “HMA” file which merges the 
GOSEQ.RES.AxN.BxN.GO.csv with the GSEPD.Segregation_P.AxN.BxN.csv such 
that name-annotated GO Terms can be sorted and selected based on their N-dimensional 
clustering validity. This table corresponds to the selected rows of Figure 3.5. 
A.2 Figures 
 
 Section A.2 is a listing of figures generated by a successful run of the tool. Like 
tables, all files are named with the run so they can be kept between runs and explored as 
needed. All figures are generated without user requesting them individually, and finding 
detailed results of a given analysis is easy with the operating system’s file-search 
commands. Like the tables, these figures are listed in the order they are generated. 
DESEQ.Volcano.AxN.BxN.png A volcano plot is a standard quality assurance 
check when performing differential expression. The y-axis is negative Log10 p-value, 
such that insignificant genes are on the bottom, and highly significant on top. The x-axis 
is the log fold change, indicating whether the gene is up- or down-regulated between 
conditions. We hope to see a mainly symmetrical response with a uniform distribution of 
gene differences and significances. This is a scatterplot with black points non-significant, 
and red with adjusted p below a threshold, giving the appearance of a volcano. 
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HM.AxN.BxN.XXX.pdf is a heatmap of gene expression for significantly 
segregating genes: rows correspond to genes and columns correspond to samples. The 
heatmap is row-normalized, such that each gene’s minimum is green and each gene’s 
maximum is red.  Here “XXX” in the filename corresponds to the number of rows (genes 
found significant by the settings of the run). The image size is automatically scaled with a 
linear function to ensure all row and column labels are legible. This can create a large file 
if many genes are selected.  The file format is kept PDF such that the user can use a 
search feature to get to a gene of interest. Four versions of this figure are included, as 
user preferences and publication requirements dictated various renditions and 
simplifications of the figure. HM is the basic, with row/column annotations, all samples 
in the input data are kept and annotated absolute expression within cells (as in Figure 
4.1).  A version “HM-.AxN.BxN.XXX.pdf” is stripped of annotations to enable tighter 
embedding in a publication where zoomed down text is unacceptable but the colors and 
correlations remain intact.  A version “HMS.AxN.BxN.XXX.pdf” is stripped of the non-
tested samples, showing only the samples in classes A and B (omitting untested samples, 
which can perturb the column ordering). Finally “HMS-AxN.BxN.XXX.pdf” is the 
combination, stripped of extraneous samples and annotations to produce the most 
compact representation of the DESeq2 results.  
GOSEQ.PWF.AxN.BxN.pdf is a byproduct of the GOSeq process. The 
“parameterized weight function” is a diagnostic of the gene set average length correction 
inherent to GOSeq. It displays the correlation between gene length and their probability 
of being found differentially expressed (this is a known bias in RNA-Seq, and the 
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primary reason for GOSeq rather than a more direct hypergeometric enrichment analysis 
for GO Term detection) [90].  
GSEPD.PCA_AG.AxN.BxN.pdf is a principal components analysis of all genes, 
scatterplot for the first two principal components. These are standard meta-analyses to 
evaluate sample clustering and batch effects visually. rgsepd annotates which samples 
belong to which classes with point colors, annotates sample IDs under each point, and 
annotates the top five driver genes along each axis.  
GSEPD.PCA_DEG.AxN.BxN.pdf is a principal components analysis of just 
differentially expressed genes, scatterplot for the first two principal components. This 
version enforces visual segregation and is more interesting for the non-tested samples’ 
clustering. rgsepd annotates which samples belong to which classes with point colors, 
annotates sample IDs under each point, and annotates the top five driver genes along each 
axis.   
 SCA.GSEPD.AxN.BxN.pdf is a series of scatterplots of the samples' Alpha 
scores with respect to two GO Terms, indicating cross-term correlations and the direction 
of divergence among outlier samples. The axes are the scale of Alpha scores, generally 0-
1 with the class A samples near (0,0) and the class B samples near (1,1) by construction.  
 GSEPD.HMA.AxN.BxN.pdf is the projection HeatMap of Alpha scores for 
significant GO Terms (Figure 3.5). Outliers with high Beta values are marked with white 
dots to indicate the cell color may not be an accurate representation of the sample's 
expression. The white dot marks are useful when a gene set cannot be reduced to a one 
dimensional axis. By virtue of the gplots package heatmap.2, we have dendrogram 
correlation by complete linkage clustering, so rows and columns are sorted by their value 
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profiles. Therefore samples with similar expression profiles are displayed near each other 
(columns), as are correlated gene sets (rows). The HMA file is the primary result shown 
in Chapter 4.   
GSEPD.HMG.AxN.BxN.pdf is the HeatMap of Gamma scores (Figure 3.7). 
The same gene sets as the previous “HMA” figure, but colored with the Euclidean 
distances as in Figure 3.4.  
Folder SCGO holds figures exploring the significant gene sets’ expression 
profiles. One to three figures per significant GO Term are generated, displaying each 
sample's behavior with respect to those genes. As a large number of figures is generated, 
these are expected to be of use only when the user is interested in exploring a select few 
GO Terms highlighted earlier in the process. 
SCGO/GSEPD.AxN.BxN.GO#.pdf is generated for each significant set. The GO 
Term name is on the title of the figure, and each pair of genes within the set is displayed 
on subsequent pages (Figure 3.5 is an example of one page of 
GSEPD.D3x2.D5x2.GO0003209.pdf.) Each sample is annotated by the expression 
values as z-scored log-scaled normalized counts, derived from the counts table. The 
Alpha axis is drawn in black between each class centroid, for diagnostic visualization. 
Non-tested samples are annotated with their scores as colored lines indicating which class 
they more closely behave like. Importantly, the drawn lines are orthogonal to the axis, 
indicating the closest possible point, but they will not appear orthogonal due to their high 
dimensional nature being projected into only two genes. These data make up the content 
of the GSEPD.HMA heatmap. 
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SCGO/Pairs.AxN.BxN.GO#.pdf files are generated for significant GO Terms 
with less than ten genes. Gene sets with few dimensions can be efficiently displayed on a 
single 'pairs' plot, for immediate visualization of a partially differentially expressed gene 
set.  Each pairing of genes is visualized as a two dimensional scatterplot.  All samples are 
displayed. Axes are labeled with the log-normalized read counts.  
SCGO/Scatter.AxN.BxN.GO#.pdf files are generated for significant GO Terms 
displaying a PCA plot. As in the GSEPD.PCA_DEG.AxN.BxN.pdf, major genes are 
annotated on each axis, and samples are labeled to facilitate visualization of outlier 
samples. This plot is the PCA across only those genes within the given GO Term, as 
extracted from the full cross product GOSEQ.RES.AxN.BxN.GO2.csv. 
 
